Peter Franz Riederer

Peter Franz Riederer's AcademicInfluence.com Rankings

Biology

#3041

World Rank

#4706

Historical Rank

Molecular Biology

#194

World Rank

#198

Historical Rank

Genetics

#213

World Rank

#258

Historical Rank

Biochemistry

#258

World Rank

#322

Historical Rank

biology Degrees

Download Badge

Biology

Peter Franz Riederer's Degrees

PhD Genetics Stanford University

Why Is Peter Franz Riederer Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Peter Franz Riederer's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Allelic Variation of Human Serotonin Transporter Gene Expression (1996) (2275)
Iron, brain ageing and neurodegenerative disorders (2004) (1599)
Transition Metals, Ferritin, Glutathione, and Ascorbic Acid in Parkinsonian Brains (1989) (1380)
Tumor necrosis factor-α (TNF-α) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients (1994) (820)
Interleukin-1β, interleukin-6, epidermal growth factor and transforming growth factor-α are elevated in the brain from parkinsonian patients (1994) (717)
Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017 (2017) (714)
Altered Brain Metabolism of Iron as a Cause of Neurodegenerative Diseases? (1994) (707)
PGC-1α, A Potential Therapeutic Target for Early Intervention in Parkinson’s Disease (2010) (699)
Brain insulin and insulin receptors in aging and sporadic Alzheimer's disease (1998) (698)
Interleukin-1β and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients (1995) (662)
Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease (1992) (588)
AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. (2014) (555)
Primary Structure of the Human Platelet Serotonin Uptake Site: Identity with the Brain Serotonin Transporter (1993) (541)
Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain (2005) (525)
Handbook of Neurochemistry and Molecular Neurobiology (2007) (516)
Selective Increase of Iron in Substantia Nigra Zona Compacta of Parkinsonian Brains (1991) (508)
AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011 (2011) (506)
Organization of the human serotonin transporter gene (2005) (490)
Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions (2010) (475)
The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry. (2004) (455)
Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. (1994) (435)
The relevance of iron in the pathogenesis of Parkinson’s disease (2011) (430)
Brain iron and ferritin in Parkinson's and Alzheimer's diseases (1990) (428)
Human brain dopamine receptors in children and aging adults (1987) (417)
Oxidative stress: Free radical production in neural degeneration (1994) (375)
Interleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkinsonian patients. (1994) (371)
Iron, neuromelanin and ferritin content in the substantia nigra of normal subjects at different ages: consequences for iron storage and neurodegenerative processes (2001) (368)
Brain-derived neurotrophic factor and neurotrophin 3 in schizophrenic psychoses (2001) (364)
Animal models of Parkinson's disease: An empirical comparison with the phenomenology of the disease in man (2005) (363)
Brain insulin system dysfunction in streptozotocin intracerebroventricularly treated rats generates hyperphosphorylated tau protein (2007) (354)
Time course of nigrostriatal degeneration in parkinson's disease (1976) (352)
Bimodal distribution of dopamine receptor densities in brains of schizophrenics. (1984) (347)
Gene expression profiling of parkinsonian substantia nigra pars compacta; alterations in ubiquitin-proteasome, heat shock protein, iron and oxidative stress regulated proteins, cell adhesion/cellular matrix and vesicle trafficking genes (2004) (337)
Human brain D1 and D2 dopamine receptors in schizophrenia, Alzheimer's, Parkinson's, and Huntington's diseases. (1987) (322)
Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients. (1995) (319)
Iron‐Melanin Complex in Substantia Nigra of Parkinsonian Brains: An X‐Ray Microanalysis (1992) (309)
Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties. (1994) (307)
MPTP mechanisms of neurotoxicity and their implications for Parkinson's disease. (1991) (305)
Neuromelanin in human dopamine neurons: Comparison with peripheral melanins and relevance to Parkinson's disease (2005) (300)
Effects of the 1-amino-adamantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel: a human postmortem brain study. (1991) (300)
Is Parkinson's disease a progressive siderosis of substantia nigra resulting in iron and melanin induced neurodegeneration? (1989) (298)
IMPLICATIONS OF COMBINED TREATMENT WITH 'MADOPAR' AND L-DEPRENIL IN PARKINSON'S DISEASE A Long-term Study (1977) (292)
Alzheimer's disease – synergistic effects of glucose deficit, oxidative stress and advanced glycation endproducts (1998) (288)
Iron‐Melanin Interaction and Lipid Peroxidation: Implications for Parkinson's Disease (1991) (282)
Determination of Advanced Glycation End Products in Serum by Fluorescence Spectroscopy and Competitive ELISA (1997) (277)
The possible role of iron in the etiopathology of parkinson's disease (1993) (275)
Advanced glycation endproducts in ageing and Alzheimer's disease (1997) (269)
Cognitive impairment in 873 patients with idiopathic Parkinson's disease (2008) (260)
Consensus paper of the WFSBP Task Force on Biological Markers: Biological Markers in Depression (2007) (254)
Pathogenesis of Parkinson's disease. (1992) (254)
Alterations in expression of glutamatergic transporters and receptors in sporadic Alzheimer's disease. (2007) (251)
Monoamine Oxidase Activity and Monoamine Metabolism in Brains of Parkinsonian Patients Treated with l‐Deprenyl (1986) (247)
New insights into the genetic etiology of Alzheimer’s disease and related dementias (2022) (246)
The 5-HT transporter gene-linked polymorphic region (5-HTTLPR) in evolutionary perspective: Alternative biallelic variation in rhesus monkeys (2005) (242)
Memantine displaces [3H]MK-801 at therapeutic concentrations in postmortem human frontal cortex. (1989) (240)
Functional promoter and polyadenylation site mapping of the human serotonin (5-HT) transporter gene (2005) (227)
Frequency of dementia, depression, and other neuropsychiatric symptoms in 1,449 outpatients with Parkinson’s disease (2010) (227)
Brain iron pathways and their relevance to Parkinson's disease. (2001) (225)
Neuroprotective Strategies in Parkinson’s Disease (2003) (221)
Selective Insolubility of α-Synuclein in Human Lewy Body Diseases Is Recapitulated in a Transgenic Mouse Model (2001) (219)
The absolute concentration of nigral neuromelanin, assayed by a new sensitive method, increases throughout the life and is dramatically decreased in Parkinson's disease (2002) (215)
Monoamine oxidase-B inhibition in Alzheimer's disease. (2004) (212)
Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry (2017) (209)
Unaltered aconitase activity, but decreased complex I activity in substantia nigra pars compacta of patients with Parkinson's disease (1994) (209)
Alzheimer‐like changes in protein kinase B and glycogen synthase kinase‐3 in rat frontal cortex and hippocampus after damage to the insulin signalling pathway (2006) (208)
Biological markers for anxiety disorders, OCD and PTSD: A consensus statement. Part II: Neurochemistry, neurophysiology and neurocognition (2017) (203)
Clinical applications of MAO-inhibitors. (2004) (203)
The flavone hispidulin, a benzodiazepine receptor ligand with positive allosteric properties, traverses the blood–brain barrier and exhibits anticonvulsive effects (2004) (202)
Crosslinking of α-synuclein by advanced glycation endproducts — an early pathophysiological step in Lewy body formation? (2000) (201)
High molecular weight hyaluronic acid inhibits advanced glycation endproduct‐induced NF‐κB activation and cytokine expression (1999) (201)
Perineuronal nets potentially protect against oxidative stress (2004) (200)
Impaired phosphorylation of cyclic AMP response element binding protein in the hippocampus of dementia of the Alzheimer type (1999) (200)
Dopamine receptor agonists in current clinical use: comparative dopamine receptor binding profiles defined in the human striatum (2003) (199)
What have we learned from the streptozotocin-induced animal model of sporadic Alzheimer’s disease, about the therapeutic strategies in Alzheimer’s research (2012) (191)
Substantia nigra neuromelanin: structure, synthesis, and molecular behaviour (2001) (187)
Evidence for oxidative stress in the frontal cortex in patients with recurrent depressive disorder—a postmortem study (2007) (187)
High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebo-controlled double-blind study (2005) (180)
Caenorhabditis elegans MPP+ Model of Parkinson’s Disease for High-Throughput Drug Screenings (2004) (178)
Decreased Catalase Activity but Unchanged Superoxide Dismutase Activity in Brains of Patients with Dementia of Alzheimer Type (1995) (174)
Influence of advanced glycation end-products and AGE-inhibitors on nucleation-dependent polymerization of beta-amyloid peptide. (1997) (171)
MAO-inhibitors in Parkinson's Disease (2011) (170)
Iron-binding characteristics of neuromelanin of the human substantia nigra. (2003) (167)
Iron accumulation in the substantia nigra in rats visualized by ultrasound. (1999) (165)
Brain iron pathways and their relevance to Parkinson's disease (2001) (161)
Degeneration of nigrostriatal dopaminergic neurons increases iron within the substantia nigra: a histochemical and neurochemical study (1994) (157)
Oxidative stress: free radical production in neural degeneration. (1994) (157)
Dopaminergic dysbalance in distinct basal ganglia neurocircuits: Implications for the pathophysiology of parkinson’s disease, schizophrenia and attention deficit hyperactivity disorder (2006) (156)
Neuronal and Glial Coexpression of Argininosuccinate Synthetase and Inducible Nitric Oxide Synthase in Alzheimer Disease (2001) (153)
Oxidative stress: a role in the pathogenesis of Parkinson's disease. (1990) (151)
Gene Expression Profiling of Sporadic Parkinson's Disease Substantia Nigra Pars Compacta Reveals Impairment of Ubiquitin‐Proteasome Subunits, SKP1A, Aldehyde Dehydrogenase, and Chaperone HSC‐70 (2005) (151)
The potentiation of the anti akinetic effect after L-Dopa treatment by an inhibitor of Mao-B, deprenil (2005) (150)
A Disturbance in the Neuronal Insulin Receptor Signal Transduction in Sporadic Alzheimer's Disease (1999) (150)
In Vitro Studies of Ferritin Iron Release and Neurotoxicity (1998) (150)
Far field potentials from the brain stem after transcutaneous vagus nerve stimulation (2003) (149)
Pharmacology of selegiline (1996) (148)
(-)-Deprenyl leads to prolongation of L-dopa efficacy in Parkinson's disease. (1983) (145)
Transforming growth factor-β1 levels are elevated in the striatum and in ventricular cerebrospinal fluid in Parkinson's disease (1995) (143)
Redox imbalance (2004) (140)
Diagnostic staging of Parkinson’s disease: conceptual aspects (2004) (139)
Alpha-lipoic acid as a new treatment option for Alzheimer [corrected] type dementia. (2001) (139)
Dopamine/glutamate interactions in Parkinson's disease (1997) (139)
Cytotoxicity of advanced glycation endproducts is mediated by oxidative stress (1998) (139)
Structure-activity relationships of flavonoid-induced cytotoxicity on human leukemia cells. (2007) (138)
Increased life expectancy resulting from addition of l-deprenyl to Madopar® treatment in Parkinson's disease: A longterm study (1985) (138)
Persistence of haloperidol in human brain tissue. (1999) (138)
Normal Mitochondrial Genome in Brain from Patients with Parkinson's Disease and Complex I Defect (1990) (136)
The alternative splicing of tau exon 10 and its regulatory proteins CLK2 and TRA2‐BETA1 changes in sporadic Alzheimer's disease (2006) (136)
Brain-derived neurotrophic factor and neurotrophin-3 levels in Alzheimer's disease brains (2000) (131)
Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline (2001) (130)
Free radical mechanisms in dementia of Alzheimer type and the potential for antioxidative treatment. (1995) (128)
A new methodology for the design of low energy buildings (2009) (126)
Isolation of a cDNA encoding the human brain serotonin transporter (2005) (125)
Consensus Paper of the WFSBP Task Force on Biological Markers of Dementia: The role of CSF and blood analysis in the early and differential diagnosis of dementia (2005) (125)
Understanding Parkinson's disease. (1997) (125)
Allelic variation of serotonin transporter expression is associated with depression in Parkinson's disease (2001) (124)
Parkinsonism in HIV dementia (2002) (122)
Primary structure of the serotonin transporter in unipolar depression and bipolar disorder (1995) (121)
Influence of neurotoxins and oxidative stress on the onset and progression of Parkinson’s disease (2000) (121)
Parkinson’s disease and depression: evidence for an alteration of the basal limbic system detected by transcranial sonography (1997) (120)
Free radicals in Parkinson's disease (2002) (118)
AGES in brain ageing: AGE-inhibitors as neuroprotective and anti-dementia drugs? (2004) (117)
Cerebral amyloid angiopathy in streptozotocin rat model of sporadic Alzheimer’s disease: a long-term follow up study (2011) (117)
Biological markers for anxiety disorders, OCD and PTSD – a consensus statement. Part I: Neuroimaging and genetics (2016) (117)
Structural Characteristics of Human Substantia Nigra Neuromelanin and Synthetic Dopamine Melanins (2000) (115)
Insulin-resistant brain state after intracerebroventricular streptozotocin injection exacerbates Alzheimer-like changes in Tg2576 AbetaPP-overexpressing mice. (2010) (114)
Progressive supranuclear palsy: clinico-pathological and biochemical studies. (1980) (112)
Transition metal-mediated glycoxidation accelerates cross-linking of beta-amyloid peptide. (2000) (111)
Free radicals in Alzheimer's disease. (1998) (111)
Therapeutic brain concentration of the NMDA receptor antagonist amantadine (1995) (111)
Iron in brain function and dysfunction with emphasis on Parkinson's disease. (1991) (110)
Potential sources of increased iron in the substantia nigra of parkinsonian patients. (2006) (108)
Mössbauer Spectroscopic Studies of Purified Human Neuromelanin Isolated from the Substantia Nigra (1995) (108)
Botulinum toxin’s axonal transport from periphery to the spinal cord (2012) (107)
Selective insolubility of alpha-synuclein in human Lewy body diseases is recapitulated in a transgenic mouse model. (2001) (107)
A molecular signature in blood identifies early Parkinson’s disease (2012) (107)
Absence of Thermal Hyperalgesia in Serotonin Transporter-Deficient Mice (2003) (107)
Management of a twenty-first century brain bank: experience in the BrainNet Europe consortium (2008) (106)
Amino acid specificity of glycation and protein–AGE crosslinking reactivities determined with a dipeptide SPOT library (1999) (105)
Localization of MAO-A and MAO-B in human brain: a step in understanding the therapeutic action of L-deprenyl. (1987) (105)
In parkinsonian substantia nigra, α-synuclein is modified by acrolein, a lipid-peroxidation product, and accumulates in the dopamine neurons with inhibition of proteasome activity (2007) (105)
Biomarkers for attention-deficit/hyperactivity disorder (ADHD). A consensus report of the WFSBP task force on biological markers and the World Federation of ADHD (2012) (104)
Cell death and apoptosis regulating proteins in Parkinson’s disease – a cautionary note (1999) (104)
Anti‐inflammatory antioxidants attenuate the expression of inducible nitric oxide synthase mediated by advanced glycation endproducts in murine microglia (2001) (103)
Modeling sporadic Alzheimer's disease: the insulin resistant brain state generates multiple long-term morphobiological abnormalities including hyperphosphorylated tau protein and amyloid-beta. (2009) (103)
Neurotrophic factors and the maldevelopmental hypothesis of schizophrenic psychoses (1998) (103)
pH measurement as quality control on human post mortem brain tissue: a study of the BrainNet Europe consortium (2009) (103)
The soluble form of Fas molecule is elevated in parkinsonian brain tissues (1996) (102)
In vivo detection of iron and neuromelanin by transcranial sonography: A new approach for early detection of substantia nigra damage (2005) (102)
Insulin-degrading enzyme in the Alzheimer's disease brain: prominent localization in neurons and senile plaques (1999) (101)
A post mortem study on neurochemical markers of dopaminergic, GABA-ergic and glutamatergic neurons in basal ganglia-thalamocortical circuits in Parkinson syndrome (1996) (101)
Impaired iron homeostasis in Parkinson's disease. (2000) (101)
Different methylation of the TNF-alpha promoter in cortex and substantia nigra: Implications for selective neuronal vulnerability (2008) (99)
Influence of neuromelanin on oxidative pathways within the human substantia nigra. (2002) (99)
Human post-mortem striatal α4β2 nicotinic acetylcholine receptor density in schizophrenia and Parkinson's syndrome (2000) (98)
Topographic immunocytochemical mapping of monoamine oxidase-A, monoamine oxidase-B and tyrosine hydroxylase in human post mortem brain stem (1988) (98)
Genetic and clinical features of progranulin-associated frontotemporal lobar degeneration. (2011) (97)
The molecular pharmacology of L-deprenyl. (1992) (97)
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in non-human primates is antagonized by pretreatment with nimodipine at the nigral, but not at the striatal level (1996) (96)
(3H]MK-801 binding sites in postmortem brain regions of schizophrenic patients (2005) (96)
Genes associated with Parkinson syndrome (2008) (95)
Brain β2-microglobulin levels are elevated in the striatum in Parkinson's diseaselevels are elevated in the striatum in Parkinson's disease (1995) (94)
Investigations on oxidative stress and therapeutical implications in dementia (1999) (94)
Dopamine D2 receptor density remains constant in treated Parkinson's disease (1986) (93)
Reduced phosphorylation of cyclic AMP-responsive element binding protein in the postmortem orbitofrontal cortex of patients with major depressive disorder (2003) (92)
Parkinson's disease: a major hypokinetic basal ganglia disorder (1999) (92)
Role of iron and iron chelation in dopaminergic‐induced neurodegeneration: Implication for Parkinson's disease (1992) (91)
MAO-B inhibitors: multiple roles in the therapy of neurodegenerative disorders? (2000) (90)
Staging of cognitive deficits and neuropathological and ultrastructural changes in streptozotocin-induced rat model of Alzheimer’s disease (2015) (89)
Noncompetitive NMDA receptor antagonists with fast open-channel blocking kinetics and strong voltage-dependency as potential therapeutic agents for Alzheimer's dementia. (1995) (88)
The neurotoxicity of iron and nitric oxide. Relevance to the etiology of Parkinson's disease. (1993) (88)
Altered redox state of platelet coenzyme Q10 in Parkinson's disease (2000) (87)
“Subcellular Proteomics” of Neuromelanin Granules Isolated from the Human Brain* (2005) (87)
Distribution of iron in different brain regions and subcellular compartments in Parkinson's disease (1992) (86)
Common variants in Alzheimer’s disease and risk stratification by polygenic risk scores (2021) (85)
TDM in psychiatry and neurology: A comprehensive summary of the consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology, update 2017; a tool for clinicians* (2018) (85)
Neuromelanin and its interaction with iron as a potential risk factor for dopaminergic neurodegeneration underlying Parkinson's disease (2009) (84)
Quantification of mRNA of tyrosine hydroxylase and aromatic L-amino acid decarboxylase in the substantia nigra in Parkinson's disease and schizophrenia (1994) (84)
Demonstration of monoamine oxidase-A and -B in the human brainstem by a histochemical technique (1989) (84)
Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017 (2018) (83)
Microglia activation is related to substantia nigra echogenicity (2010) (82)
Pretreatment with nimodipine prevents MPTP-induced neurotoxicity at the nigral, but not at the striatal level in mice. (1995) (82)
Excitotoxicity and new antiglutamatergic strategies in Parkinson's disease and Alzheimer's disease. (2007) (82)
Constituents of sage (Salvia officinalis) with in vitro affinity to human brain benzodiazepine receptor. (2003) (81)
Microglial activation induces cell death, inhibits neurite outgrowth and causes neurite retraction of differentiated neuroblastoma cells (2003) (81)
Degeneration of neuronal cells due to oxidative stress--microglial contribution. (2002) (81)
Advanced glycation end products in neurodegeneration: More than early markers of oxidative stress? (1998) (80)
Iron and ferritin in substantia nigra in Parkinson's disease. (1993) (80)
The role of iron in senescence of dopaminergic neurons in Parkinson's disease. (1993) (80)
Enhancement of central nervous system pathology in early simian immunodeficiency virus infection by dopaminergic drugs (2001) (79)
Increased xanthine oxidase in the thalamus and putamen in depression (2010) (79)
Schizophrenia: From the brain to peripheral markers. A consensus paper of the WFSBP task force on biological markers (2009) (77)
Neurochemical perspectives to the function of monoamine oxidase (1989) (77)
Platelet MAO‐B activity and the psychopathology of Parkinson's disease, senile dementia and multi‐infarct dementia (1988) (76)
Insertion/deletion variant (−141C Ins/Del) in the 5′ regulatory region of the dopamine D2 receptor gene: lack of association with schizophrenia and bipolar affective disorder (1998) (76)
Memantine Upregulates BDNF and Prevents Dopamine Deficits in SIV-Infected Macaques: A Novel Pharmacological Action of Memantine (2008) (76)
Dopamine receptor agonists in the therapy of Parkinson’s disease (2004) (75)
A QUALITATIVE AND QUANTITATIVE STUDY OF SUGAR‐ALCOHOLS IN SEVERAL FOODS (1973) (75)
Increased brain levels of 4-hydroxy-2-nonenal glutathione conjugates in severe Alzheimer's disease (2006) (75)
Iron in neurodegenerative disorders (2002) (74)
Abnormal Localization of Two Neuronal Calcium Sensor Proteins, Visinin-Like Proteins (VILIPs)-1 and -3, in Neocortical Brain Areas of Alzheimer Disease Patients (2001) (74)
A review of the mechanisms and role of monoamine oxidase inhibitors in Parkinson’s disease (2004) (74)
α-Synuclein in Parkinson’s disease: causal or bystander? (2019) (71)
Analysis of expression of cholecystokinin in dopamine cells in the ventral mesencephalon of several species and in humans with schizophrenia. (1990) (71)
Cloning and functional characterization of the human norepinephrine transporter gene promoter (1998) (71)
Neurochemical and behavioural features induced by chronic low dose treatment with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset: Implications for Parkinson's disease? (1991) (71)
The enigma of neuromelanin in Parkinson's disease substantia nigra. (1994) (71)
The Neuronal Calcium Sensor Protein VILIP-1 Is Associated with Amyloid Plaques and Extracellular Tangles in Alzheimer's Disease and Promotes Cell Death and Tau Phosphorylation in Vitro: A Link between Calcium Sensors and Alzheimer's Disease? (2001) (71)
Biomarker candidates of neurodegeneration in Parkinson’s disease for the evaluation of disease-modifying therapeutics (2011) (70)
Modulation of monoamine oxidase (MAO) expression in neuropsychiatric disorders: genetic and environmental factors involved in type A MAO expression (2016) (69)
The neurobiological link between OCD and ADHD (2014) (69)
Age-dependent memory loss, synaptic pathology and altered brain plasticity in the Drosophila mutant cardinal accumulating 3-hydroxykynurenine (2000) (69)
Neuroprotection by dopamine agonists. (1994) (69)
The cognition-enhancing drug tenilsetam is an inhibitor of protein crosslinking by advanced glycosylation (1994) (69)
Tyrosine Hydroxylase Activity in Caudate Nucleus from Parkinson's Disease: Effects of Iron and Phosphorylating Agents (1988) (68)
The diabetic brain and cognition (2017) (67)
Anti-melanin antibodies are increased in sera in Parkinson's disease (2009) (67)
Interleukin-2 but not basic fibroblast growth factor is elevated in parkinsonian brain (2005) (66)
Regulation of PAX-6 gene transcription: alternate promoter usage in human brain. (1998) (66)
Affinity of 1-aminoadamantanes for the σ binding site in post-mortem human frontal cortex (1993) (66)
Neurochemical insights into monoamine oxidase inhibitors, with special reference to deprenyl (selegiline) (1983) (66)
Neuromelanin induces oxidative stress in mitochondria through release of iron: mechanism behind the inhibition of 26S proteasome (2006) (65)
New insights on the genetic etiology of Alzheimer’s and related dementia (2020) (64)
Pharmacotoxic psychosis after memantine in Parkinson's disease (1991) (64)
The effect of simian immunodeficiency virus infection in vitro and in vivo on the cytokine production of isolated microglia and peripheral macrophages from rhesus monkey. (1996) (64)
The serotonin transporter in Alzheimer's and Parkinson's disease. (2000) (64)
Characterization and regional distribution of nitric oxide synthase in the human brain during normal ageing (1999) (63)
(‐)Deprenyl in the Treatment of Parkinson's Disease (1982) (63)
Biochemical fundamentals of Parkinson's disease. (1988) (63)
NADPH-diaphorase/nitric oxide synthase containing neurons in normal and Parkinson's disease putamen (1994) (63)
Increased tissue copper and manganese content in the lentiform nucleus in primary adult‐onset dystonia (1999) (62)
CNS Modulation of adrenal tyrosine hydroxylase in Parkinson's disease and metabolic encephalopathies. (1978) (61)
Up-regulation of striatal adenosine A2A receptors in schizophrenia (2003) (61)
Ontogenesis of monoamine oxidase-A and -B in the human brain frontal cortex (1989) (61)
Neurochemical aspects of the Rett syndrome (1985) (61)
[3H]MK-801 binding sites in post-mortem human frontal cortex. (1989) (61)
Dolichol is the major lipid component of human substantia nigra neuromelanin (2005) (61)
Room thermal modelling adapted to the test of HVAC control systems (2002) (61)
Gene expression as peripheral biomarkers for sporadic Alzheimer's disease. (2009) (60)
Altered regulation of brain glucose metabolism as a cause of neurodegenerative disorders? (1995) (60)
Involvement of dopamine in the progression of AIDS Dementia Complex (2002) (60)
Free radicals in Alzheimer's dementia: currently available therapeutic strategies. (1998) (60)
Molecular mechanisms for neurodegeneration. Synergism between reactive oxygen species, calcium, and excitotoxic amino acids. (1996) (59)
Pilot study: peripheral biomarkers for diagnosing sporadic Parkinson’s disease (2010) (59)
Functional Neurochemistry of Alzheimers Disease (2004) (59)
Dopamine D3 receptor gene polymorphism and alcohol dependence: relation to personality rating. (1999) (58)
Pharmacological aspects of the neuroprotective effects of irreversible MAO-B inhibitors, selegiline and rasagiline, in Parkinson’s disease (2018) (58)
Relating mode of action to clinical practice: dopaminergic agents in Parkinson's disease. (2007) (58)
The role of iron in the basal ganglion. (1990) (58)
Transforming growth factor-beta 1 levels are elevated in the striatum and in ventricular cerebrospinal fluid in Parkinson's disease. (1995) (57)
A promoter-associated polymorphic repeat modulates PAX-6 expression in human brain. (1998) (57)
Glutamatergic-dopaminergic balance in the brain. Its importance in motor disorders and schizophrenia. (1992) (56)
Pathogenesis and preclinical course of Parkinson's disease. (1999) (56)
Aldehyde dehydrogenase (ALDH) in Alzheimer’s and Parkinson’s disease (2016) (56)
Alzheimer’s Disease. Epidemiology, Neuropathology, Neurochemistry, and Clinics (1990) (56)
From benefit to damage. Glutamate and advanced glycation end products in Alzheimer brain (2006) (55)
DOPAMINE RECEPTORS AND SCHIZOPHRENIA: DRUG EFFECT OR ILLNESS (1980) (55)
Biochemical and pharmacological characterization of 1-trichloromethyl-1,2,3,4-tetrahydro-beta-carboline: a biologically relevant neurotoxin? (2002) (55)
Oxidative-stress associated parameters (lactoferrin, superoxide dismutases) in serum of patients with Alzheimer's disease. (1996) (55)
The significance of neuronal lateralisation in Parkinson’s disease (2012) (55)
Dopamine and noradrenalin in the cerebrospinal fluid of schizophrenic patients (1983) (54)
Susceptibility for schizophrenia is not influenced by a functional insertion/deletion variant in the promoter of the serotonin transporter gene (1998) (54)
Gene expression profile in streptozotocin rat model for sporadic Alzheimer’s disease (2004) (54)
Lateralisation in Parkinson disease (2018) (54)
The glucocorticoid receptor gene exon 1-F promoter is not methylated at the NGFI-A binding site in human hippocampus (2007) (53)
Distinction between benign and malignant type of parkinson's disease (1979) (53)
Slow accumulation of psychotropic substances in the human brain. Relationship to therapeutic latency of neuroleptic and antidepressant drugs? (1995) (53)
Comparison analysis of gene expression patterns between sporadic Alzheimer's and Parkinson's disease. (2007) (53)
The AGNP-TDM Expert Group Consensus Guidelines: focus on therapeutic monitoring of antidepressants (2005) (53)
Advanced glycation endproducts are associated with Hirano bodies in Alzheimer's disease (1998) (53)
Increased dopaminergic neurotransmission in therapy-naïve asymptomatic HIV patients is not associated with adaptive changes at the dopaminergic synapses (2010) (53)
Genetic risk factors and markers for Alzheimer's disease and/or depression in the VITA study. (2009) (52)
Potential genetic markers of sporadic Alzheimer's dementia (2001) (52)
Dementia in Parkinson's disease and (pre) senile dementia of Alzheimer type: morphological aspects and changes in the intracerebral MAO activity. (1984) (52)
Therapeutic Monitoring of Psychotropic Drugs: An Outline of the AGNP-TDM Expert Group Consensus Guideline (2004) (52)
The link between iron, metabolic syndrome, and Alzheimer’s disease (2011) (52)
Hippocampal level of neural specific adenylyl cyclase type I is decreased in Alzheimer's disease. (2000) (52)
Variations of monoamines and their metabolites in the human brain putamen (1992) (51)
Amphetamine and 2-phenylethylamine in post-mortem Parkinsonian brain after (-)deprenyl administration (2005) (51)
Classification of advanced stages of Parkinson’s disease: translation into stratified treatments (2017) (51)
Complement C1q and C3 mRNA expression in the frontal cortex of Alzheimer's patients (1995) (50)
Identification of L-ferritin in Neuromelanin Granules of the Human Substantia Nigra (2009) (50)
HUPO Brain Proteome Project: Summary of the pilot phase and introduction of a comprehensive data reprocessing strategy (2006) (50)
Advanced glycation endproducts-associated parameters in the peripheral blood of patients with Alzheimer's disease. (1996) (50)
The neuromelanin of human substantia nigra: structure, synthesis and molecular behaviour. (2003) (50)
Mitochondrial DNA in Postmortem Brain from Patients with Parkinson's Disease (1991) (50)
Preliminary brain autopsy findings in progredient Rett syndrome. (1986) (50)
Human post-mortem striatal alpha4beta2 nicotinic acetylcholine receptor density in schizophrenia and Parkinson's syndrome. (2000) (49)
Early institution of bromocriptine in Parkinson's disease inhibits the emergence of levodopa-associated motor side effects. Long-term results of the PRADO study (2005) (49)
Brain-derived neurotrophic factor (BDNF) and neurotrophin 3 (NT3) levels in post-mortem brain tissue from patients with depression compared to healthy individuals – a proof of concept study (2017) (49)
Early impairment in dopaminergic neurotransmission in brains of SIV‐infected rhesus monkeys due to microglia activation (2005) (49)
Modulation of simian immunodeficiency virus neuropathology by dopaminergic drugs (2004) (49)
Oxygen Free Radicals and Neurodegeneration in Parkinson's Disease: A Role for Nitric Oxide a (1994) (48)
Antioxidant capacity in postmortem brain tissues of Parkinson's and Alzheimer's diseases. (2006) (48)
Blood transferrin and ferritin in Alzheimer's disease. (1997) (48)
Gene expression alterations in brain areas of intracerebroventricular streptozotocin treated rat. (2006) (47)
The human dopamine transporter gene: the 5′-flanking region reveals five diallelic polymorphic sites in a Caucasian population sample (2001) (47)
Glutamate receptor antagonists for neuroleptic malignant syndrome and akitetic hyperthermic Parkinsonian crisis (1993) (47)
The TaClo concept: 1-trichloromethyl-1,2,3,4-tetrahydro-beta-carboline (TaClo), a new toxin for dopaminergic neurons. (1995) (47)
Inflammatory Pathways in Parkinson's Disease; A BNE Microarray Study (2012) (47)
Loss of human hippocampal adenosine A1 receptors in dementia: evidence for lack of specificity (1998) (47)
Evidence for specific phases in the development of human neuromelanin (2006) (46)
Regulation of glutathione and cell toxicity following exposure to neurotropic substances and human immunodeficiency virus-1 in vitro. (1997) (46)
The role of monoamine oxidase, iron-melanin interaction, and intracellular calcium in Parkinson's disease. (1990) (46)
Use of monoamine oxidase inhibitors in chronic neurodegeneration (2017) (46)
Changes in the expression of genes related to neuroinflammation over the course of sporadic Alzheimer’s disease progression: CX3CL1, TREM2, and PPARγ (2015) (45)
Normal lymphocyte responsiveness to lectins but impaired sensitivity to in vitro glucocorticoids in major depression. (1991) (45)
The tyrosine kinase inhibitor imatinib mesylate delays prion neuroinvasion by inhibiting prion propagation in the periphery (2011) (45)
Oxidative stress in the brain at early preclinical stages of mouse scrapie (2006) (45)
Dopamine receptors and schizophrenia: the neuroleptic drug problem. (1981) (44)
Neuroprotective therapeutic strategies. Comparison of experimental and clinical results. (1995) (44)
Serotonin Depletion Hampers Survival and Proliferation in Neurospheres Derived from Adult Neural Stem Cells (2010) (44)
3H-spiperone binding sites in post-mortem brains from schizophrenic patients: Relationship to neuroleptic drug treatment, abnormal movements, and positive symptoms (2005) (44)
Homospecific activity (activity per enzyme protein) of tyrosine hydroxylase increases in parkinsonian brain (2005) (44)
How a neuropsychiatric brain bank should be run: a consensus paper of Brainnet Europe II (2006) (44)
Effect of lipoic acid on redox state of coenzyme Q in mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and diethyldithiocarbamate. (1994) (44)
Selegiline enhances survival and neurite outgrowth of MPP(+)-treated dopaminergic neurons. (1994) (44)
Brain beta 2-microglobulin levels are elevated in the striatum in Parkinson's disease. (1995) (44)
Monoamine oxidase-B inhibitors in the treatment of Parkinson’s disease: clinical–pharmacological aspects (2018) (44)
Toxic clozapine serum levels during inflammatory reactions. (2009) (44)
Multi-target iron-chelators improve memory loss in a rat model of sporadic Alzheimer's disease. (2015) (44)
The influence of smoking on the serum level of duloxetine. (2008) (44)
Advanced glycation endproducts change glutathione redox status in SH-SY5Y human neuroblastoma cells by a hydrogen peroxide dependent mechanism (2001) (43)
Neuromelanin inhibits enzymatic activity of 26S proteasome in human dopaminergic SH-SY5Y cells (2004) (43)
Tyrosinase is not detected in human catecholaminergic neurons by immunohistochemistry and Western blot analysis. (2007) (43)
Parkinson’s Disease and Related Disorders (2006) (43)
Comparison of benzodiazepine receptor binding in membranes from human or rat brain (1985) (43)
Effect of antemortem and postmortem factors on [3H]glutamate binding in the human brain (1988) (43)
Glutamatergic drugs in Parkinson's disease. (1994) (43)
Selegiline is neuroprotective in primary brain cultures treated with 1-methyl-4-phenylpyridinium. (1996) (42)
The competitive NMDA antagonist CPP protects substantia nigra neurons from MPTP-induced degeneration in primates (1993) (42)
Diabetes Type II: A Risk Factor for Depression–Parkinson–Alzheimer? (2011) (42)
The neurochemistry of Alzheimer type, vascular type and mixed type dementias compared. (1996) (42)
Borna disease virus in human brains with a rare form of hippocampal degeneration but not in brains of patients with common neuropsychiatric disorders. (1999) (41)
Neurotransmission in HIV associated dementia: a short review (2001) (41)
Reduced immunoreactivity of adenylyl cyclase in dementia of the Alzheimer type (1996) (40)
Consensus paper of the WFSBP Task Force on Biological Markers: Criteria for biomarkers and endophenotypes of schizophrenia part I: Neurophysiology (2015) (40)
Reduced Brain Antioxidant Capacity in Rat Models of Betacytotoxic-Induced Experimental Sporadic Alzheimer’s Disease and Diabetes Mellitus (2007) (40)
Combined enrichment of neuromelanin granules and synaptosomes from human substantia nigra pars compacta tissue for proteomic analysis. (2013) (40)
Neurotoxicity and neuroprotection in Parkinson's disease. (1992) (40)
Nine-month follow-up of the insulin receptor signalling cascade in the brain of streptozotocin rat model of sporadic Alzheimer’s disease (2015) (40)
Iron in Central Nervous System Disorders (2001) (40)
Iron in the Parkinsonian substantia nigra. (1997) (40)
Dopamine activates HIV in chronically infected T lymphoblasts (2000) (40)
Iron, copper, zinc, magnesium, and calcium in postmortem brain tissue from schizophrenic patients (1994) (39)
On the mode of action of L-deprenyl in the human central nervous system (2005) (39)
Subcellular proteomics reveals neuromelanin granules to be a lysosome-related organelle (2006) (39)
Susceptibility of Brains from Patients with Alzheimer's Disease to Oxygen-Stimulated Lipid Peroxidation and Differential Scanning Calorimetry (1992) (39)
Dopamine metabolism and neurotransmission in primate brain in relationship to monoamine oxidase A and B inhibition (2005) (38)
Intranigral injected iron progressively reduces striatal dopamine metabolism (1994) (38)
Integrity of the blood-CSF barrier in dementia of Alzheimer type: CSF/serum ratios of albumin and IgG (2005) (38)
Identification of benzodiazepines in Artemisia dracunculus and Solanum tuberosum rationalizing their endogenous formation in plant tissue. (2000) (38)
Disturbed glucocorticoid receptor autoregulation and corticotropin response to dexamethasone in depressives pretreated with metyrapone (1991) (38)
Mosaicism for a serotonin transporter gene promoter-associated deletion: decreased recombination in depression (1999) (37)
Dramatic increase of α-hydroxyaldehydes derived from plasmalogens in the aged human brain (1997) (37)
Selegiline’s neuroprotective capacity revisited (2003) (37)
Neuroprotective profile of the multitarget drug rasagiline in Parkinson's disease. (2011) (37)
Neuromelanin is an immune stimulator for dendritic cells in vitro (2011) (37)
Levels and proteolytic processing of chromogranin A and B and secretogranin II in cerebrospinal fluid in neurological diseases (1998) (37)
Early Diagnosis and Preventive Therapy in Parkinson’s Disease (1989) (36)
MATLAB / SIMULINK FOR BUILDING AND HVAC SIMULATION-STATE OF THE ART (2005) (36)
Morphological Abnormalities in Nitric-Oxide-Synthase-Positive Striatal Interneurons of Schizophrenic Patients (2005) (36)
Quantitative analysis of the structural requirements for blockade of the N-methyl-D-aspartate receptor at the phencyclidine binding site. (1998) (36)
Alterations of guanine nucleotide-binding proteins in post-mortem human brain in alcoholics (1993) (36)
L-deprenyl plus l-phenylalanine in the treatment of depression (2005) (35)
Regional and age-dependent expression of the nitric oxide receptor, soluble guanylyl cyclase, in the human brain (2001) (35)
Oxidative stress related markers in the “VITA” and the centenarian projects (2005) (35)
Evidence for specific phases in the development of human neuromelanin (2006) (35)
Nitric oxide in the pathogenesis of Parkinson's disease. (1999) (35)
Functional neurochemistry of Alzheimer's disease. (2004) (35)
Nitroxyl oxidizes NADPH in a superoxide dismutase inhibitable manner. (2001) (35)
Chronic alcohol consumption and cerebral indices of oxidative stress: is there a link? (2001) (35)
Determination of trace elements in the human substantia nigra (2005) (35)
Scavestrogens protect IMR 32 cells from oxidative stress-induced cell death. (1998) (35)
Increased activity of mitochondrial aldehyde dehydrogenase (ALDH) in the putamen of individuals with Alzheimer's disease: a human postmortem study. (2010) (34)
GC/MS analysis of thermally degraded neuromelanin from the human substantia nigra (2004) (34)
Biochemical lesions of the nigrostriatal system by TaClo (1-trichloromethyl-1,2,3,4-tetrahydro-beta-carboline) and derivatives. (1995) (34)
Effect of antemortem and postmortem factors on [3H]MK-801 binding in the human brain: transient elevation during early childhood. (1989) (34)
Naturally occurring benzodiazepines: current status of research and clinical implications (2000) (34)
Proteomic characterization of neuromelanin granules isolated from human substantia nigra by laser-microdissection (2016) (34)
Methylmercury induces neurite degeneration in primary culture of mouse dopaminergic mesencephalic cells (2002) (34)
Macaque animal model for HIV-induced neurological disease (2002) (34)
Parkinson’s Disease: Biochemistry, Clinical Pathology, and Treatment (1983) (33)
1-Trichloromethyl-1,2,3,4-tetrahydro-β-carboline increases extracellular serotonin and stimulates hydroxyl radical production in rats (1998) (33)
Alpha-1-antichymotrypsin bi-allele polymorphism, apolipoprotein-E tri-allele polymorphism and genetic risk of Alzheimer's syndrome (1995) (33)
Effects of gender and age on serum concentrations of antidepressants under naturalistic conditions (2013) (33)
Reduced concentrations and increased metabolism of biogenic amines in a single case of Rett-syndrome: apostmortem brain study (2005) (33)
Selegiline: a molecule with innovative potential (2019) (33)
Excretion of biogenic amine metabolites in anorexia nervosa. (1982) (32)
Cerebral oligaemia episode triggers free radical formation and late cognitive deficiencies (2000) (32)
Responsibility of extrastriatal areas for the appearance of psychotic symptoms (Clinical and biochemical human post-mortem findings) (2005) (32)
Biogenic amines and metabolites in spinal cord of patients with Parkinson's disease and amyotrophic lateral sclerosis (1991) (32)
New lexicon and criteria for the diagnosis of Alzheimer's disease (2011) (32)
Consensus paper of the WFSBP Task Force on Biological Markers: Criteria for biomarkers and endophenotypes of schizophrenia, part III: Molecular mechanisms (2017) (32)
Transmitter Biochemistry of Human Brain Tissue (1981) (32)
Neuromelanin selectively induces apoptosis in dopaminergic SH‐SY5Y cells by deglutathionylation in mitochondria: involvement of the protein and melanin component (2008) (31)
Chronic monoamine oxidase-B inhibitor treatment blocks monoamine oxidase-A enzyme activity (2014) (31)
Association study of the 5-HTTLPR polymorphism and depression in 75-Year-Old nondemented subjects from the Vienna Transdanube Aging (VITA) study. (2006) (31)
Pathochemical Markers in Major Psychoses (1985) (31)
Effects of tranylcypromine stereoisomers on monamine oxidation in man. (1980) (31)
Neurotoxicity of Acetaldehyde‐Derived Advanced Glycation End Products for Cultured Cortical Neurons (2003) (31)
The dopamine receptor agonist lisuride attenuates iron-mediated dopaminergic neurodegeneration (2003) (31)
Rat brain glucose transporter-2, insulin receptor and glial expression are acute targets of intracerebroventricular streptozotocin: risk factors for sporadic Alzheimer’s disease? (2017) (31)
Homozygosity at the dopamine D3 receptor gene in schizophrenic patients (1996) (31)
Continuous versus pulsatile administration of rotigotine in 6-OHDA-lesioned rats: contralateral rotations and abnormal involuntary movements (2008) (31)
Considerations for measuring iron in post-mortem tissue of Parkinson’s disease patients (2012) (31)
Consensus paper of the WFSBP Task Force on Biological Markers: Criteria for biomarkers and endophenotypes of schizophrenia part II: Cognition, neuroimaging and genetics (2016) (30)
Cell-mediated immunity and its glucocorticoid-sensitivity after clinical recovery from severe major depressive disorder. (1992) (30)
Effects of methylphenidate: the cellular point of view (2010) (30)
Differential effects of human neuromelanin and synthetic dopamine melanin on neuronal and glial cells (2005) (30)
Evidence for increased oxidative stress in alcohol-dependent patients provided by quantification of in vivo salicylate hydroxylation products. (1997) (29)
Depression and care-dependency in Parkinson's disease: results from a nationwide study of 1449 outpatients. (2012) (29)
Neurotransmitters and Disorders of the Basal Ganglia (1999) (29)
Lewy Bodies: A Spectator or Salient Killer? (2015) (29)
Involvement of microglia in cerebrospinal fluid glutamate increase in SIV-infected rhesus monkeys (Macaca mulatta). (1999) (29)
Monoamine metabolite levels in CSF of SIV‐infected rhesus monkeys (Macaca mulatta) (1997) (28)
Reduced thermal hyperalgesia and enhanced peripheral nerve injury after hind paw inflammation in mice lacking the serotonin‐transporter (2008) (28)
Acetylcholine in human CSF: methodological considerations and levels in dementia of Alzheimer type (1998) (28)
Alteration of the pro-oxidant xanthine oxidase (XO) in the thalamus and occipital cortex of patients with schizophrenia (2011) (28)
Platelet Monoamine Oxidase B Activity in Dementia (1998) (28)
Neuromelanin-bound ferric iron as an experimental model of dopaminergic neurodegeneration in Parkinson's disease. (2008) (28)
Hydrogen peroxide enhances the activity of monoamine oxidase type-B but not of type-A: a pilot study. (1986) (28)
Neuropsychopharmacology of the Trace Amines (1985) (28)
Quantitative reduction of type I adenylyl cyclase in human alcoholics. (1999) (28)
Proteomics of the human brain: sub-proteomes might hold the key to handle brain complexity (2006) (28)
Quantitation of 5HT3 receptors in forebrain of serotonin transporter deficient mice (2004) (28)
Biochemical post-mortem findings in depressed patients (2005) (28)
Norepinephrine transporter gene (NET) variants in patients with panic disorder (2002) (28)
Radical scavenging compound J 811 inhibits hydrogen peroxide‐induced death of cerebellar granule cells (1999) (27)
Neuron-specific alterations in signal transduction pathways associated with Alzheimer's disease. (2014) (27)
MPTP-Induced Parkinsonian Syndrome (1999) (27)
Glucagon-like peptide-1 mediates effects of oral galactose in streptozotocin-induced rat model of sporadic Alzheimer’s disease (2018) (27)
Aldehyde dehydrogenase 2 in sporadic Parkinson's disease. (2014) (26)
Increased levels of calcium-sensitive adenylyl cyclase subtypes in the limbic system of alcoholics: evidence for a specific role of cAMP signaling in the human addictive brain (2001) (26)
In vivo and in vitro effects of glucocorticoids on lymphocyte proliferation in man: relationship to glucocorticoid receptors. (1990) (26)
Deprenyl prolongs the therapeutic efficacy of combined L-DOPA in Parkinson's disease. (1984) (26)
Chronic TVP-1012 (rasagiline) dose--activity response of monoamine oxidases A and B in the brain of the common marmoset. (1998) (26)
Widespread differences in cortex DNA methylation of the “language gene” CNTNAP2 between humans and chimpanzees (2014) (26)
Therapeutic drug monitoring of tricyclic antidepressants in everyday clinical practice. (2007) (26)
Nucleus ruber and L-Dopa psychosis: Biochemical post-mortem findings (2005) (25)
Chronic exogenous corticosterone administration generates an insulin-resistant brain state in rats (2010) (25)
Treatment with antioxidants does not prevent loss of dopamine in the striatum of MPTP-treated common marmosets: Preliminary observations (1991) (25)
Long-term behavioural effects of TaClo (1-trichloromethyl-1,2,3,4-tetrahydro-beta-carboline) after subchronic treatment in rats. (1995) (25)
Reduced concentrations of ascorbic acid and glutathione in a single case of Rett syndrome: A postmortem brain study (1987) (25)
(r)-, but not (s)-alpha lipoic acid stimulates deficient brain pyruvate dehydrogenase complex in vascular dementia, but not in Alzheimer dementia (2004) (25)
Physical stress-induced secretion of adrenal and pituitary hormones in patients with atopic eczema compared with normal controls. (2009) (25)
Orphenadrine is an uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist: binding and patch clamp studies (2005) (25)
Differential Alterations in Metabolism and Proteolysis-Related Proteins in Human Parkinson’s Disease Substantia Nigra (2018) (25)
The thiobarbituric acid assay reflects susceptibility to oxygen induced lipid peroxidation in vitro rather than levels of lipid hydroperoxides in vivo: A methodological approach (1993) (25)
Oral and parenteral nutrition with L-Valine: mode of action. (1980) (25)
Brain choline acetyltransferase reduction in SIV infection. An index of early dementia? (2000) (25)
Acute MPTP treatment produces no changes in mitochondrial complex activities and indices of oxidative damage in the common marmoset ex vivo one week after exposure to the toxin (1996) (25)
Psychiatric complications in human immunodeficiency virus infection. (2002) (25)
Age-dependent changes in memory and mushroom bodies in the Drosophila mutant vermilion deficient in the kynurenine pathway of tryptophan metabolism. (1999) (25)
Changes in the cAMP-related signal transduction mechanism in postmortem human brains of heroin addicts (2001) (25)
Expression, but not activity, of neuronal nitric oxide synthase is regionally increased in the alcoholic brain. (2001) (24)
Brain antioxidant capacity in rat models of betacytotoxic-induced experimental sporadic Alzheimer's disease and diabetes mellitus. (2007) (24)
Characterization of cognitive deficits in spontaneously hypertensive rats, accompanied by brain insulin receptor dysfunction (2015) (24)
A rapid assay of 4-hydroxy-3-methoxyphenylglycol in urine. (1975) (24)
The role of neurotransporters in excitotoxicity, neuronal cell death, and other neurodegenerative processes (1996) (24)
Neurotoxic effects on the dopaminergic system induced by TaClo (1-trichloromethyl-1,2,3,4-tetrahydro-β-carboline), a potential mammalian alkaloid : in vivo and in vitro studies (1996) (24)
Inhibition of [3H]α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid [AMPA] binding by the anticonvulsant valproate in clinically relevant concentrations: an autoradiographic investigation in human hippocampus (1998) (24)
Association study of BDNF and CNTF polymorphism to depression in non-demented subjects of the "VITA" study. (2006) (24)
Neurotransmission and the ontogeny of human brain (2005) (24)
Ca2+/CaM-sensitive adenylyl cyclase activity is decreased in the Alzheimer's brain: Possible relation to type I adenylyl cyclase (2005) (24)
Polymorphic MAO-A and 5-HT-Transporter Genes: Analysis of Interactions in Panic Disorder (2000) (24)
Erratum to “Alpha-lipoic acid as a new treatment option for Alzheimer type dementia” [Arch. Gerontol. Geriatr. 32 (2001) 275–282] (2010) (23)
Regional distribution of [3H]MK-801 binding sites in the human brain (1989) (23)
Brain monoamines in hepatic encephalopathy and other types of metabolic coma. (1978) (23)
Morphological and biochemical changes in the aging brain: pathophysiological and possible therapeutic consequences. (1982) (23)
The 5-HT transporter genel inked polymorphic region ( 5H T T L P R ) in evolut ionary perspective : alternative biallelic variation in rhesus m o n k e y s Rapid Communication (23)
Characterization of [3H]pentazocine binding sites in post-mortem human frontal cortex (2005) (23)
Long-Term Effects of Intracerebroventricular Streptozotocin Treatment on Adult Neurogenesis in the Rat Hippocampus. (2015) (23)
Analyses of energy metabolism and mitochondrial genome in post-mortem brain from patients with Alzheimer's disease (1993) (22)
Iron as the concert master in the pathogenic orchestra playing in sporadic Parkinson’s disease (2021) (22)
New horizons in molecular mechanisms underlying Parkinson's disease and in our understanding of the neuroprotective effects of selegiline. (1996) (22)
Unaltered brain levels of 1,N 2-propanodeoxyguanosine adducts of trans-4-hydroxy-2-nonenal in Alzheimer's disease (2002) (22)
Alzheimer Disease—No Target for Statin Treatment. A Mini Review (2007) (22)
Role of dopamine D3 and serotonin 5-HT1A receptors in l-DOPA-induced dyskinesias and effects of sarizotan in the 6-hydroxydopamine-lesioned rat model of Parkinson’s disease (2011) (22)
Glutamate receptor antagonism: neurotoxicity, anti-akinetic effects, and psychosis. (1991) (22)
Apolipoprotein E genotype in Spanish schizophrenic patients. (2000) (22)
An Introduction to neurotransmission in health and disease (1990) (22)
The balance of biogenic amines as condition for normal behaviour (2005) (22)
Strategies for the protection of dopaminergic neurons against neurotoxicity (2009) (22)
Brain catalase in the streptozotocin-rat model of sporadic Alzheimer’s disease treated with the iron chelator–monoamine oxidase inhibitor, M30 (2015) (22)
Intrathecal viral replication and cerebral deficits in different stages of human immunodeficiency virus disease (2011) (22)
Altered P300 topography due to functional and structural disturbances in the limbic system in dementia and psychoses and to pharmacological conditions (1989) (22)
Cellular action of MAO inhibitors. (1987) (22)
Influence of sensor position in building thermal control: criteria for zone models (2002) (22)
Evolutionary conserved microsatellites in the promoter region of the 5-hydroxytryptamine receptor 2C gene (HTR2C) are not associated with bipolar disorder in females (2002) (21)
Immunofluorescence cytochemistry on thin frozen sections of human substantia nigra for staining of monoamine oxidase A and monoamine oxidase B: a pilot study. (1990) (21)
Alzheimer's disease and type 2 diabetes: Two diseases, one common link? (2013) (21)
Bromocriptine lessens the incidence of mortality in L-Dopa-treated parkinsonian patients: Prado-study discontinued (2005) (21)
N-methyl-(R)-salsolinol and its relevance to Parkinson's disease (1998) (21)
Interaction of valproic acid and antidepressant drugs (2012) (21)
Dopaminergic supersensitivity in parkinsonism. (1975) (21)
Neural predictive control for single-speed ground source heat pumps connected to a floor heating system for typical French dwelling (2014) (21)
Increases in CSF dopamine in HIV patients are due to the dopamine transporter 10/10-repeat allele which is more frequent in HIV-infected individuals (2013) (21)
Affinity of 1-aminoadamantanes for the sigma binding site in post-mortem human frontal cortex. (1993) (21)
The antiparkinsonian drug budipine binds to NMDA and sigma receptors in postmortem human brain tissue. (1995) (21)
Changes of some putative neurotransmitters in human cerebral infarction. (1978) (20)
The Pathophysiological Basis of Parkinson’s Disease (1993) (20)
Memantine inhibits [3H]MK-801 binding to human hippocampal NMDA receptors. (1994) (20)
Selegiline completely restores choline acetyltransferase activity deficits in simian immunodeficiency infection. (2001) (20)
Elevated glucocorticoid receptor concentrations before and after glucocorticoid therapy in peripheral mononuclear leukocytes of patients with atopic dermatitis. (1991) (20)
2-Phenylethylamine and amphetamine in human brain: effects of L-deprenyl in Parkinson's disease [proceedings]. (1979) (20)
Amantadine: reappraisal of the timeless diamond—target updates and novel therapeutic potentials (2021) (20)
Is there neuroprotection in Parkinson syndrome? (2000) (20)
Is selegiline neuroprotective in Parkinson's disease? (1994) (20)
Circadian Rhythms of Human Pineal Melatonin, Related Indoles, and Beta Adrenoreceptors: Post‐Mortem Evaluation (1990) (19)
Increased concentrations of manganese superoxide dismutase in serum of alcohol-dependent patients. (1997) (19)
Excretion of beta-carbolines harman and norharman in 24-hour urine of chronic alcoholics during withdrawal and controlled abstinence. (1996) (19)
Genes and oxidative stress in parkinsonism: cDNA microarray studies. (2003) (19)
LC with Column-Switching and Spectrophotometric Detection for Determination of Risperidone and 9-Hydroxyrisperidone in Human Serum (2008) (19)
Development of a testing method for control HVAC systems by emulation (2002) (19)
Manipulation of neurotransmitters by acupuncture (?) (1975) (19)
Neuroleptic drugs in the human brain (2006) (19)
Structural investigations of neuromelanin by pyrolysis-gas chromatography/mass spectrometry (2006) (19)
Arguments for the use of dopamine receptor agonists in clinical and preclinical Parkinson's disease. (2003) (19)
A MULTIZONE BUILDING MODEL FOR MATLAB / SIMULINK ENVIRONMENT (2005) (19)
Mini-Review: Multiple developmental forms of parkinsonism. The basis for further research as to the pathogenesis of parkinsonism (2002) (19)
Levodopa in the treatment of Parkinson's disease: Current controversies (2005) (19)
Neurotransmitters in CSF of idiopathic adult-onset dystonia: Reduced 5-HIAA levels as evidence of impaired serotonergic metabolism (2005) (18)
Region specific distribution of levomepromazine in the human brain (2006) (18)
Drosophila mutants of the kynurenine pathway as a model for ageing studies. (2003) (18)
Cholinergic and monoaminergic neuromediator systems in DAT. Neuropathological and neurochemical findings (1990) (18)
Neuroleptic drugs in the human brain: clinical impact of persistence and region-specific distribution. (2006) (18)
Neue Hypothese zur Ätiopathogenese des Alzheimer-Syndroms Advanced glycation endproducts (AGEs) (1996) (18)
Entacapone increases and prolongs the central effects of l-DOPA in the 6-hydroxydopamine-lesioned rat (2004) (18)
Exonic variants of the GABAB receptor gene and panic disorder (2000) (18)
NADPH-diaphorase staining reveals new types of interneurons in human putamen (2003) (18)
Impairment of Gsα function in human brain cortex of Alzheimer’s disease: comparison with normal aging (2004) (18)
Investigations on the point mutations at nt 5460 of the mtDNA in different neurodegenerative and neuromuscular diseases. (1996) (18)
Changes in cerebral receptors for gamma aminobutyric acid in patients with hepatic encephalopathy. (2008) (18)
Parkinson's disease and the electron transport chain in postmortem brain. (1993) (18)
Ciliary neurotrophic factor (CNTF) genotypes: influence on choline acetyltransferase (ChAT) and acetylcholine esterase (AChE) activities and neurotrophin 3 (NT3) concentration in human post mortem brain tissue. (1997) (18)
The relevance of glial monoamine oxidase‐B and polyamines to the action of selegiline in parkinson's disease (1993) (18)
Early Detection of Parkinson’s Disease: Unmet Needs (2008) (17)
Coronaviruses: a challenge of today and a call for extended human postmortem brain analyses (2020) (17)
Numerical Evaluation of Earth to Air Heat Exchangers and Heat Recovery Ventilation Systems (2007) (17)
Altered expression of calcium‐ and apoptosis‐regulating proteins in multiple system atrophy purkinje cells (2000) (17)
Consensus paper of the WFSBP task force on biological markers: Biological markers for alcoholism (2013) (17)
Dopamine-sensitive adenylate cyclase activity in the caudate nucleus and adrenal medulla in Parkinson's disease and in liver cirrhosis. (1978) (17)
Increased frequency of the α‐1‐antichymotrypsin T allele in cerebral amyloid angiopathy (2000) (17)
Effects of botulinum toxin type A facial injection on monoamines and their metabolites in sensory, limbic and motor brain regions in rats (2016) (17)
Recent advances in pharmacological therapy of Parkinson's disease. (1993) (17)
Functional characterization of the human PAX3 gene regulatory region. (1999) (17)
Association of a functional NOS1 promoter repeat with Alzheimer's disease in the VITA cohort. (2011) (17)
Determination of Monoamine Oxidase A and B Activity in Long-Term Treated Patients With Parkinson Disease (2017) (17)
Cholinergic neurotransmission seems not to be involved in depression but possibly in personality. (1995) (17)
Differential alteration of adenylyl cyclase subtypes I, II, and V/VI in postmortem human brains of heroin addicts. (1998) (17)
Neurochemical abnormalities in Alzheimer's disease and Parkinson's disease--a comparative review. (1997) (17)
Genetic variation in the choline O-acetyltransferase gene in depression and Alzheimer's disease: the VITA and Milano studies. (2011) (16)
Terguride: partial dopamine agonist in the treatment of Parkinson's disease. (1987) (16)
Value and actuality of the prescription information for therapeutic drug monitoring of psychopharmaceuticals: a comparison with the medico-scientific evidence. (2007) (16)
Human cerebral free amino acids in hepatic coma. (1978) (16)
Variants in neurotrophic factor genes and schizophrenic psychoses: no associations in a Spanish population (1997) (16)
Dopamine deficits and regulation of the cAMP second messenger system in brains of simian immunodeficiency virus-infected rhesus monkeys (2004) (16)
New approach to evaluate the seasonal performance of building integrated geothermal heat pump system (2011) (16)
Neural degeneration in Parkinson's disease. (2001) (16)
Highly Halogenated Tetrahydro-β-Carbolines as a New Class of Dopaminergic Neurotoxins (1998) (16)
Iron-Melanin Interaction and Parkinson's Disease (1993) (16)
Streptozotocin Impairs Proliferation and Differentiation of Adult Hippocampal Neural Stem Cells in Vitro-Correlation With Alterations in the Expression of Proteins Associated With the Insulin System (2018) (16)
Alteration of glutamyltranspeptidase binding proteins in postmortem brains of heroin addicts. (1996) (16)
Interaction of neuroprotective substances with human brain superoxide dismutase. An in vitro study. (1995) (16)
Brain monoamines in human hepatic encephalopathy (1978) (16)
Human Genetic Diseases (2015) (16)
The Role of Dopamine in the Control of Neurobiological Functions (1989) (16)
Neuron-specific mitochondrial DNA deletion levels in sporadic Alzheimer's disease. (2013) (16)
Symptoms and side effects in the course of Parkinson's disease. (1983) (16)
Platelet monoamine oxidase B activity in dementia. A 4-year follow-up. (1998) (16)
A null mutation allele in the CNTF gene and schizophrenic psychoses. (1996) (15)
COUPLING OF TRNSYS WITH SIMULINK – A METHOD TO AUTOMATICALLY EXPORT AND USE (2009) (15)
Excitotoxins l-β-oxalyl-amino-alanine (l-BOAA) and 3, 4, 6-trihydroxyphenylalanine (6-OH-DOPA) inhibit [3H]α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA) binding in human hippocampus (1994) (15)
Mechanisms underlying and medical management of l-Dopa-associated motor complications (2011) (15)
Clinical and biochemical effects of the selective phosphodiesterase inhibitor rolipram in depressed inpatients controlled by determination of plasma level. (1988) (15)
Different effects of soluble and aggregated amyloid β42 on gene/protein expression and enzyme activity involved in insulin and APP pathways (2012) (15)
Development of A Simulation Platform for the Evaluation of District Energy System Performances (2015) (15)
Biochemical actions of l‐deprenyl (selegiline) * (1994) (15)
Glia Protects Neurons against Extracellular Human Neuromelanin (2007) (15)
Nimodipine inhibits [3H]nitrobenzylthioinosine binding to the adenosine transporter in human brain. (1993) (15)
Adenosine A1 receptors in human hippocampus: inhibition of [3H]8-cyclopentyl-1,3-dipropylxanthine binding by antagonist drugs (1993) (15)
Practical importance of neuroprotection in Parkinson's disease (2002) (15)
The Role of Brain Dopamine (1989) (15)
L-dopa competes with tyrosine and tryptophan for human brain uptake. (1980) (15)
Dopamine metabolism in human brain: effect of monoamine oxidase inhibition in vitro by (-)deprenyl and (+) and (-) tranylcypromine. (1980) (15)
Investigation of association of serotonin transporter and monoamine oxidase‐A genes with Alzheimer's disease and depression in the VITA study cohort: A 90‐month longitudinal study (2014) (15)
Guidelines for the standardized collection of blood-based biomarkers in psychiatry: Steps for laboratory validity – a consensus of the Biomarkers Task Force from the WFSBP (2019) (14)
Correlation between Apolipoprotein-E polymorphism and Alzheimer's disease pathology. (2000) (14)
Lymphocyte glucocorticoid receptor binding during depression and after clinical recovery. (1991) (14)
Levodopa in the treatment of (PRE) senile dementia (1980) (14)
CNTF and endogenous psychoses? (1996) (14)
Peripheral-type benzodiazepine receptors in diagnostic subtypes of schizophrenic patients (1998) (14)
Effect of adding selegeline to levodopa in early, mild Parkinson's disease. "On treatment" rather than intention to treat analysis should have been used. (1996) (14)
Functional polymorphisms of the 5-HT1A and 5-HT1B receptor are associated with clinical symptoms in migraineurs (2007) (14)
Heterotopic rat heart transplantation: severe loss of glutathione in 8-hour ischemic hearts. (2004) (14)
Involvement of transmitter systems in neuropsychiatric diseases (1993) (14)
Plasma moclobemide and metabolites: lack of correlation with clinical response and biogenic amines (2004) (14)
Monoamine oxidase activity during (--)-deprenil therapy: human brain post-mortem studies. (1978) (14)
Dramatic increase of alpha-hydroxyaldehydes derived from plasmalogens in the aged human brain. (1997) (14)
3H-spiroperidol binding to human peripheral mononuclear cells: Methodological aspects (1992) (14)
Tryptophan is a marker of human postmortem brain tissue quality (2009) (13)
Direct sequencing of the reserpine‐sensitive vesicular monoamine transporter complementary DNA in unipolar depression and manic depressive illness (1994) (13)
Cholinergic-adrenergic balance: Part 2. Relationship between drug sensitivity and personality (1990) (13)
Regional differences in the interaction of the excitotoxins domoate and L-β-oxalyl-amino-alanine with [3H]kainate binding sites in human hippocampus (1995) (13)
VITA study: white matter hyperintensities of vascular and degenerative origin in the elderly. (2007) (13)
Brain aging phenomena in migrating sockeye salmon Oncorhynchus nerka nerka (2005) (13)
Nitrocellulose redox permanganometry: A simple method for reductive capacity assessment (2020) (13)
Brain monoamines in metabolic coma and stroke. (1978) (13)
Estrogen receptor beta gene (ESRbeta) 3'-UTR variants in Alzheimer disease. (2006) (13)
Milacemide, the selective substrate and enzyme-activated specific inhibitor of monoamine oxidase B, increases dopamine but not serotonin in caudate nucleus of rhesus monkey (1990) (13)
Quantitative dissection of human brain areas: relevance to transmitter analyses. (1980) (13)
DL-3,4-threo-DOPS in Parkinson's disease: Effects on orthostatic hypotension and dizziness (2005) (13)
[New hypothesis on etiopathogenesis of Alzheimer syndrome. Advanced glycation end products (AGEs)]. (1996) (13)
Iron-dependent enzymes in Parkinson's disease. (1995) (13)
Monoamine oxidase A and B inhibitors in Parkinson's disease. (2007) (13)
Single intracerebroventricular injection of botulinum toxin type A produces slow onset and long-term memory impairment in rats (2009) (13)
Determination of glutathione, glutathione disulphide, ascorbic acid and dehydroascorbic acid in tissues by reversed-phase liquid chromatography with electrochemical detection (1991) (12)
Estrogen receptor 1 gene (ESR1) variants in panic disorder. (2002) (12)
The role of alpha-synuclein as ferrireductase in neurodegeneration associated with Parkinson’s disease (2020) (12)
Methyl- and acetyltransferases are stable epigenetic markers postmortem (2011) (12)
The effect of neuromelanin on the proteasome activity in human dopaminergic SH-SY5Y cells. (2006) (12)
The motor circuit of the human basal ganglia reconsidered. (2000) (12)
Characterization of Glucocorticoid Binding Capacity in Human Mononuclear Lymphocytes: Increase by Metyrapone is Prevented by Dexamethasone Pretreatment (1990) (12)
Increased synaptic markers in hippocampus of depressed patients (2005) (12)
The impact of methylphenidate and its enantiomers on dopamine synthesis and metabolism in vitro (2017) (12)
Extensive sequence divergence between the human and rat brain vesicular monoamine transporter: Possible molecular basis for species differences in the susceptibility to MPP+ (2005) (12)
U‐373 MG glioblastoma and IMR‐32 neuroblastoma cell lines express the dopamine and vesicular monoamine transporters (1996) (12)
Time sequences of dopaminergic cell death in Parkinson's disease: indications for neuroprotective studies. (1999) (12)
Brain glucose transporter protein 2 and sporadic Alzheimer’s disease (2010) (12)
Disorder-specific effects of polymorphisms at opposing ends of the Insulin Degrading Enzyme gene (2011) (12)
Methylphenidate enhances neural stem cell differentiation (2013) (12)
Clinical, biochemical and psychometric findings with the new MAO-A-inhibitors moclobemide and brofaromine in patients with major depressive disorder. (1990) (12)
Reduced immunoreactivity of type I adenylyl cyclase in the postmortem brains of alcoholics. (1998) (12)
Brain monoamines in metabolic (endotoxic) coma a preliminary biochemical study in human postmortem material (2005) (12)
Tools for optimising pharmacotherapy in psychiatry (therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests): focus on antidepressants (2021) (12)
The Therapeutic Place and Value of Present and Future MAO-B Inhibitors — l-Deprenyl as the Gold Standard (1993) (12)
Effects of nimodipine on the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced depletions in the biogenic amine levels in mice. (1993) (12)
Shared cerebral metabolic pathology in non-transgenic animal models of Alzheimer's and Parkinson's disease (2020) (12)
Views on neurodegeneration as a basis for neuroprotective strategies. (2004) (12)
Histochemistry of MAO subtypes in the brainstem of humans: a relation to the radical hypothesis of Parkinson’s disease? (1989) (11)
Glutathione redox status in mitochondria and cytoplasm differentially and sequentially activates apoptosis cascade in dopamine-melanin-treated SH-SY5Y cells (2009) (11)
4‐HYDROXY‐3‐METHOXYPHENYLGLYCOL AS AN INDEX OF BRAIN NORADRENALINE TURNOVER IN ENDOGENOUS DEPRESSION (1980) (11)
The daily rhythm of HVA, VMA, (VA) and 5-HIAA in depressionsyndrom (2005) (11)
In vivo and in vitro effects of glucocorticoids on lymphocyte proliferation in depression (2005) (11)
High dose selegiline augments striatal ubiquinol in mouse: an indication of decreased oxidative stress or of interference with mitochondrial respiration? A pilot study. (1995) (11)
Exonic variants of the GABA(B) receptor gene and panic disorder. (2000) (11)
Reduced sensitivity to ethanol of Gsα and Gi/oα in the cerebral cortex of alcoholic patients (1994) (11)
Imbalance of the Gs and Gi/o function in post-mortem human brain of depressed patients (2005) (11)
Biological aspects of depression in Parkinson's disease. (1986) (11)
Brain quinolinic acid in Alzheimer's dementia (2005) (11)
Measurement of receptor-mediated functional activation of G proteins in postmortem human brain membranes (1998) (11)
The relevance of preclinical studies for the treatment of Parkinson's disease (2003) (11)
Lamotrigine in the treatment of nocturnal myoclonus syndrome (NMS): two case reports (2005) (11)
The Effect of Artificial and Natural Sunlight upon Some Psychosomatic Parameters of the Human Organism (1982) (11)
The Role of Iron in the Pathogenesis of Parkinson's Disease (2006) (11)
Association between a null mutation in the human ciliary neurotrophic factor (CNTF) gene and increased of psychiatric diseases? (1996) (11)
Dynamic Test Method for the Determination of the Global Seasonal Performance Factor of Heat Pumps Used for Heating, Cooling and Domestic Hot Water Preparation (2009) (11)
Disruption of excitatory amino acid transporters in brains of SIV‐infected rhesus macaques is associated with microglia activation (2007) (10)
Biochemical Anatomy of the Basal Ganglia and Associated Neural Systems (1999) (10)
Monoamine oxidase inhibition and CNS immunodeficiency infection. (2004) (10)
(3H)dipyridamole and (3H)nitrobenzylthioinosine binding sites at the human parietal cortex and erythrocyte adenosine transporter: a comparison. (1994) (10)
Therapeutic drug monitoring of psychotropics: report of a consensus conference. (1992) (10)
Senile dementia of Alzheimer’s type and Parkinson’s disease: neurochemical overlaps and specific differences (1990) (10)
The Nigral Coup in Parkinson’s Disease by α-Synuclein and Its Associated Rebels (2021) (10)
Combination treatment with selective monoamine oxidase inhibitors and dopaminergic agonists in Parkinson's disease: biochemical and clinical observations. (1983) (10)
Increased hippocampal DNA oxidation in serotonin transporter deficient mice (2002) (10)
The effect of piribedil on l-DOPA-induced dyskinesias in a rat model of Parkinson’s disease: differential role of α2 adrenergic mechanisms (2012) (10)
Urinary dopamine sulfate: regulations and significance in neurological disorders. (1990) (10)
Proteomic Characterization of Synaptosomes from Human Substantia Nigra Indicates Altered Mitochondrial Translation in Parkinson’s Disease (2020) (10)
A short review on the relation between the dopamine transporter 10/10-repeat allele and ADHD: implications for HIV infection (2014) (10)
Determination of a wide range of urinary amine metabolites using a simple high-performance liquid chromatographic technique. (1981) (9)
Effects of glucocorticoids on plasma catecholamines in depression (1989) (9)
Flibanserin attenuates l-DOPA-sensitized contraversive circling in the unilaterally 6-hydroxydopamine-lesioned rat model of Parkinson’s disease (2011) (9)
A MATHEMATICAL MODEL OF THE DOPAMINERGIC SYNAPSE: STABILITY AND SENSITIVITY ANALYSES, AND SIMULATION OF PARKINSON'S DISEASE AND AGING PROCESSES (1982) (9)
Consensus on minimal criteria of clinical and neuropathological diagnosis of schizophrenia and affective disorders for post mortem research (1995) (9)
MAO — The Mother of all Amine Oxidases (1998) (9)
Explorative results from multistep screening for potential genetic risk loci of Alzheimer’s disease in the longitudinal VITA study cohort (2017) (9)
Longevity in Parkinson's disease treated with L-DOPA (1974) (9)
Pathobiochemistry of the extrapyramidal system: a “short note” review (1989) (9)
Changes in pyruvate dehydrogenase complex (PDHc) activity and [3H]QNB-receptor binding in rat brain subsequent to intracerebroventricular injection of bromopyruvate (1990) (9)
LRP10 in α-synucleinopathies (2018) (9)
Perspective: Treatment for Disease Modification in Chronic Neurodegeneration (2021) (9)
MPTP induced dopaminergic neurotoxicity—a useful model in the study of parkinson's disease? (1987) (9)
Comparison of chocolate to cacao-free white chocolate in Parkinson’s disease: a single-dose, investigator-blinded, placebo-controlled, crossover trial (2012) (9)
SLC6A2 and SLC6A4 Variants interact with Venlafaxine Serum Concentrations to Influence Therapy Outcome (2014) (9)
Regional distribution and characterization of nitric oxide synthase activity in the brain of the common marmoset. (1995) (8)
Thermal room modelling adapted to the test of hvac control systems (2001) (8)
Investigation of the lipid component of neuromelanin (2006) (8)
Brain monoamines in human cerebral infarcts (1978) (8)
Glucocortinoid receptors on mononuclear leukocytes in Alzheimer's disease (1990) (8)
The Comparison of Brand-Name and Generic Formulations of Venlafaxine: A Therapeutic Drug Monitoring Analysis (2014) (8)
[EEG- and biochemical findings in Kleine-Levin-syndrome. A case report (author's transl)]. (1981) (8)
A novel technique for the isolation of Lewy bodies in brain (1998) (8)
Antioxidant capacity in rat brain after intracerebroventricular treatment with streptozotocin and alloxan--a preliminary study. (2008) (8)
Influence of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, lipoic acid and L-deprenyl on the interplay between cellular redox systems. (1994) (8)
Astrocyte- and Microglia-Specific Mitochondrial DNA Deletions Levels in Sporadic Alzheimer's Disease. (2019) (8)
Ciliary neurotrophic factor null mutation and schizophrenia in a Swedish population (1997) (8)
[Pharmacotherapy of Alzheimer dementia: therapy of cognitive symptoms--new results of clinical studies]. (1997) (8)
Psychiatric, nonmotor aspects of Parkinson's disease. (2012) (8)
L-glutamate and L-aspartate concentrations in the developing and aging human putamen tissue (2005) (8)
The pharmacology of Parkinson's disease: l-dopa and beyond (1984) (8)
Simultaneous determination of MAO-A and -B activity following first time intake of an irreversible MAO-B inhibitor in patients with Parkinson’s disease (2017) (8)
[Epidemiology of Parkinson's Disease and Current Concepts of Outpatient Care in Germany]. (2017) (8)
The pathogenesis of HIV-induced dementia (2002) (8)
The central catechol-O-methyltransferase inhibitor tolcapone increases striatal hydroxyl radical production in l-DOPA/carbidopa treated rats (2009) (8)
Oxidative stress and neuroprotection (2006) (8)
Toshiharu (Toshi) Nagatsu: an appreciation (2017) (8)
Transcriptional alterations under continuous or pulsatile dopaminergic treatment in dyskinetic rats (2011) (8)
The Mode of Action of MAO-B Inhibitors (1993) (8)
L-dopa level in plasma, primary condition for the kinetic effect (2005) (8)
The Gly/Glu polymorphism of the neurotrophin 3 gene: allele frequencies in a Caucasian population and relevance for psychiatric disorders. (1996) (8)
Basic science in Parkinson’s disease: its impact on clinical practice (2011) (8)
Cognitive, behavioral and metabolic effects of oral galactose treatment in the transgenic Tg2576 mice (2019) (8)
The dopamine-related polymorphisms BDNF, COMT, DRD2, DRD3, and DRD4 are not linked with changes in CSF dopamine levels and frequency of HIV infection (2017) (7)
Antioxidant capacity in rat brain after ICV treatment with streptozotocin and alloxan — a preliminary study (2008) (7)
Biochemical Membrane Constituents and Activities of Alkaline and Acid Phosphatase and Cathepsin in Cortical and Subcortical Brain Areas in Dementia of the Alzheimer Type (1991) (7)
Amine Oxidases and Their Impact on Neurobiology (1990) (7)
Biochemical and morphological changes in the aging brain. (1985) (7)
The N-methyl-d-aspartate receptor channel blocker amantadine does not cause histopathological alterations in human brain tissue (1999) (7)
[Pathomechanisms and hypothesis-guided therapeutic strategies for late-onset Alzheimer's disease]. (2003) (7)
Pharmacokinetic Characterization of Amantadine in Human Brain Tissue (2006) (7)
Neuropsychiatric Drugs Against COVID-19: What is the Clinical Evidence? (2022) (7)
Blood-based biomarker in Parkinson’s disease: potential for future applications in clinical research and practice (2022) (7)
Transitional states of central serotonin receptors in Parkinson's disease (2005) (7)
Interaction of valproic acid and the antidepressant drugs doxepin and venlafaxine: analysis of therapeutic drug monitoring data under naturalistic conditions (2014) (7)
MAO-B-Inhibitor selegiline (R-(-)-deprenyl). A new therapeutic concept in the treatment of Parkinson's disease. Proceedings of the international symposium. Berlin, January 23-25, 1987. (1987) (7)
Injection of a minuscule dose of FeCl3 within the ventrolateral striatum causes a chronic disturbance of the integrative function within the limbic part of the ventral striatum (1995) (7)
Effect of lazaroid U-74389G on iron-induced reduction of striatal dopamine metabolism. (1995) (7)
[Dementia and depression determine care dependency in Parkinson's disease: analysis of 1,449 outpatients receiving nursing care in Germany]. (2011) (7)
Benign and malignant types of Parkinson's disease: clinical and patho-physiological characterization. (1980) (7)
Characterization of antibody affinities using an AGE-modified dipeptide spot library. (2002) (7)
[The German Study on the Epidemiology of Parkinson's Disease with Dementia (GEPAD): more than Parkinson]. (2010) (7)
Brain Monoamines in Cerebral Infarction and Coma (1979) (7)
Pilot study: potential transcription markers for adult attention-deficit hyperactivity disorder in whole blood (2012) (7)
Is Galactose a Hormetic sugar? An Exploratory Study of the Rat Hippocampal Redox Regulatory Network. (2021) (7)
Development of a multiobjective optimization procedure dedicated to the design of district energy concept (2018) (7)
Non-coding RNA as a trigger of neuropathologic disorder phenotypes in transgenic Drosophila (2008) (7)
Brain tryptophan rather than pH-value is altered as consequence of artificial postmortem interval and storage conditions (2010) (7)
Regional distribution and characterization of nitric oxide synthase activity in the brain of the common marmoset (1995) (7)
Is there a subtype of developmental Parkinson's disease? (2009) (7)
A critical review of evidence for preclinical differences between rasagiline and selegiline (2012) (6)
Brain Biochemistry in Schizophrenia: An Assessment (1985) (6)
No Metagenomic Evidence of Causative Viral Pathogens in Postencephalitic Parkinsonism Following Encephalitis Lethargica (2021) (6)
[Therapeutic drug monitoring (TDM) of psychotropic drugs: a consensus guideline of the AGNP-TDM group]. (2006) (6)
The Dopaminergic and Glutamatergic Systems in Schizophrenia (1990) (6)
Tranylcypromine isomers in the treatment of Parkinson's disease. Biochemical effects. (1981) (6)
Immunoreactivity of cAMP response element binding protein is not altered in the post-mortem cerebral cortex or cerebellum of alcoholics. (2001) (6)
Monoamine Oxidase Type B Inhibitors in Human and Animal Parkinsonism (1986) (6)
Neurofibrillary tangles without cell loss in the lateral vestibular nucleus of patients with Alzheimer's disease (1994) (6)
Effect of post-mortem storage on synaptic 5-HT binding and uptake in mammalian brain (2005) (6)
[2-year experiences with a combination treatment of Parkinsonism with L-dopa and a decarboxylase inhibitor (Benserazid, Ro 4-4602)]. (1974) (6)
Studies on the neurotransmitter binding to pig brain microvessels. (1983) (6)
Allelic variation of a functional promoter polymorphism of the serotonin transporter and depression in Parkinson's disease. (2007) (6)
A Physicochemical Approach to Characterize [3H] -Tryptamine-Binding-Sites in Human Brain (1985) (6)
Binding of the ligand [3H]MK-801 to the MK-801 binding site of the N-methyl-D-aspartate receptor during experimental encephalopathy from acute liver failure and from acute hyperammonemia in the rabbit (1993) (6)
FROM SIZING AND HYDRAULIC BALANCING TO CONTROL USING THE SIMBAD TOOLBOX (2003) (6)
Brain Iron and other Trace Metals in Neurodegenerative Diseases (2000) (6)
Reduced sensitivity to ethanol of Gs alpha and Gi/o alpha in the cerebral cortex of alcoholic patients. (1994) (6)
[Current biochemical hypotheses of endogenous depression]. (1985) (6)
Naturally occurring benzodiazepines may codetermine chronotypes (2001) (6)
Contribution of disturbed iron metabolism to the pathogenesis of Parkinson's disease (2008) (6)
Iron-Melanin Interaction in Substantia Nigra as the Neurotoxic Component of Parkinson’s Disease (1990) (6)
The glycine binding site of the NMDA receptor: involvement in neurodegeneration and new approach for neuroprotection. (1994) (6)
Neuromelanin and Nigrostriatal Dopamine Neuron Degeneration (1993) (6)
Distribution pattern of monoamine oxidase a and monoamine oxidase b in human substantia nigra shown by immunofluorescence cytochemistry on thin frozen sections (1988) (5)
Biological Role of Neuromelanin in the Human Brain and Its Importance in Parkinson's Disease (2011) (5)
The role of MAO in dopaminergic transmission. (1990) (5)
A STATISTICAL METHOD TO IMPROVE THE ENERGY EFFICIENCY OF AN OFFICE BUILDING (2007) (5)
Thermal Building Modelling Adapted to District Energy Simulation (2015) (5)
Is galactose a hormetic sugar? Evidence from rat hippocampal redox regulatory network (2021) (5)
Brain Neurotransmitter Amines in Cerebral Ischemia and Stroke (1981) (5)
Workshop II: “Neuroprotection”– the Lugano consensus (2000) (5)
Central Aminergic Function and its Disturbance by Hepatic Disease: The Current Status of L-valine Pharmacotherapy in Metabolic Coma (1981) (5)
Creation of a gene expression classifier for predicting Parkinson’s disease rate of progression (2020) (5)
SIMULATION MODELS FOR TESTING CONTROL SYSTEMS FOR HVAC APPLICATIONS (2001) (5)
Melanin and Neuromelanin Fluorescence Studies Focusing on Parkinson’s Disease and Its Inherent Risk for Melanoma (2019) (5)
Postnatal ontogeny of GTP binding protein in the human frontal cortex. (1999) (5)
District MOdeller and SIMulator (DIMOSIM) – A dynamic simulation platform based on a bottom-up approach for district and territory energetic assessment (2021) (5)
Progressive Neurodegeneration of the Dopaminergic system and Inhibition of the Complex I Induced by the Chloral-Derived Tetrahydro-β-Carboline TaClo (1996) (5)
Introduction to the special issue on monoamine oxidase A and B: eternally enigmatic isoenzymes (2018) (5)
14C-Tryptamine Binding in Parkinson’s Disease and Hepatic Coma (1984) (5)
Safety of Cerebrolysin for Neurorecovery after Acute Ischemic Stroke: A Systematic Review and Meta-Analysis of Twelve Randomized-Controlled Trials (2021) (5)
CNS AND ADRENAL GLAND TYROSINE HYDROXYLASE AND THE INFLUENCE OF DRUG TREATMENT ON cAMP - ACTIVITY IN PARKINSON'S DISEASE - HUMAN POST MORTEM STUDIES (1979) (5)
Pharmacology Manipulation of neurotransmitters by acupuncture (?) (a preliminary communication) J. Neural Transm., 37 (1975) 81–94 (1976) (4)
Secondary (toxic) parkinsonism as model of Parkinson's disease. (1988) (4)
Therapeutic drug monitoring of antidepressants in haemodialysis patients. (2012) (4)
Effects of Selegiline in a retroviral rat model for neurodegenerative disease. (1999) (4)
P-2-66 Multiple and single dose pharmacokinetics of milnacipran in major depressive patients (1995) (4)
Axonal transport of botulinum toxin A from periphery to CNS in sensory and motor nerves (2012) (4)
Tranylcypromine isomers in Parkinson's disease. Effect of low doses on monoamine oxidase inhibition and blood pressure response. (1983) (4)
741 Regional distribution of insulin, insulin receptors and IGF-I receptors in post-mortem brain cortex in aging and in dementia of Alzheimer type (1996) (4)
Dopamine and Noradrenaline in the Magno- and Parvocellular Portions of the Red Nucleus (1981) (4)
N-methyl-D-aspartate (NMDA) antagonists in Parkinson's disease. (1993) (4)
Potential Biomarkers of Parkinson's Disease (2007) (4)
[Biochemical findings in the brain in endogenous depression]. (1975) (4)
Iron, Neuromelanin, and α-Synuclein in Neuropathogenesis of Parkinson's Disease (2003) (4)
Time course of manganese superoxide dismutase concentrations in serum of alcohol-dependent patients during abstinence. (1997) (4)
3H-spiroperidol binding to peripheral mononuclear cells in schizophrenic and healthy subjects (1993) (4)
Effects of long-term recovery from transient cerebral ischemia in rat brain: Tissue levels of acetylcholine, monoamines, and their metabolites (1993) (4)
Brofaromine (CGP 11 305 A) in treatment of depression: biological estimation of plasma concentrations. (1990) (4)
SLC6A2 and SLC6A4 Variants interact with Venlafaxine Serum Concentrations to Influence Therapy Outcome (2014) (4)
Phenylethylamine and phenylacetic acid in CSF of schizophrenics and healthy controls (1982) (4)
The industrial chemical Tinuvin 123 does not induce dopaminergic neurotoxicity in C57Bl/6 mice (2000) (4)
Pigmentation in the human brain and risk of Parkinson's disease (2010) (4)
Integrity of the blood-CSF-barrier in dementia of the Alzheimer type (1989) (4)
Association between a null mutation in the human ciliary neurotrophic factor (CNTF) gene and increased incidence of psychiatric diseases? (1996) (4)
Reduction of cortical muscarinic receptors after inhibition of pyruvate dehydrogenase complex (PDHc) in rats—a model of dementia? (1989) (4)
Distribution of the B33 CTG repeat polymorphism in a subtype of schizophrenia (1998) (4)
Can enzyme kinetics of prooxidants teach us a lesson about the treatment of Alzheimer's disease: A pilot post-mortem study (2010) (4)
Laboratory assessments in the course of Parkinson’s disease: a clinician’s perspective (2015) (4)
Effects of L-deprenyl and amantadine in an MPTP-model of parkinsonism. (1990) (4)
Biomarkers for Early Detection of Parkinson's Disease: An Essential Challenge (2008) (3)
Electrophoresis of unconcentrated natural cerebrospinal fluid (2005) (3)
Correction: Methylphenidate enhances neural stem cell differentiation (2013) (3)
Personality: Neurobehavioural Foundation and Pharmacological Protocols (2014) (3)
[Antagonism of the ammonia effect on serotonin receptors by L-valine]. (1982) (3)
[Therapeutic drug monitoring in neuropsychopharmacology : Summary of the consensus guidelines 2017 of the TDM task force of the AGNP]. (2019) (3)
Triplet repeats in clinical subtypes of schizophrenia: variation at the DRPLA (B 37 CAG repeat) locus is not associated with periodic catatonia Short Communication (1994) (3)
Laser Microdissection-Based Protocol for the LC-MS/MS Analysis of the Proteomic Profile of Neuromelanin Granules. (2021) (3)
Neuromelanin may Mediate Neurotoxicity via its Interaction with Redox Active Iron (2000) (3)
Neurochemical markers as potential indicators of postmortem tissue quality. (2018) (3)
[Biochemistry of hepatic encephalopathy]. (1978) (3)
The implications of increased iron in parkinsonian substantia nigra and its high affinity binding to melanin for dopamine neuron degeneration (1990) (3)
The distribution and metabolism of L-tryptophan in healthy probands under dietary conditions. (1980) (3)
Different modes of action of catecholamine-O-methyltransferase inhibitors entacapone and tolcapone on adenylyl cyclase activity in vitro (2002) (3)
Erythrocyte membrane proteins in psychiatric disorders and controls. (1988) (3)
A highly sensitive method for the determination of protein bound 3,4-dihydroxyphenylalanine as a marker for post-translational protein hydroxylation in human tissues ex vivo (2001) (3)
Tranylcypromine Isomers in Parkinson’s Disease (1983) (3)
Central administration of alloxan impairs glucose tolerance in rats (2005) (3)
[Neurochemical perspectives of the function of monoamine oxidases]. (1989) (3)
On the determination of free L-tryptophan. (1975) (3)
IRS 2 Insulin receptor substrate-2 (2017) (3)
Brain iron and schizophrenia (1993) (3)
Senile dementia of the Alzheimer type (SDAT): Cholinergic and monoaminergic neuromediator profils in postmortem cortex cerebri (1989) (3)
Glucocorticoid receptors on mononuclear leukocytes in Alzheimer's disease. (1990) (3)
A study of brain dopamine sulfate levels in relation to free dopamine and homovanillic acid in Parkinson's disease. (1991) (3)
Neuromelanin granules of the substantia nigra: proteomic profile provides links to tyrosine hydroxylase, stress granules and lysosomes (2022) (3)
Nootropics (1993) (3)
ADVANCED GLYCATION END PRODUCT (AGE) INHIBITION AS A POSSIBLE PHARMACOTHERAPEUTIC STRATEGY IN THE TREATMENT OF ALZHEIMER'S DISEASE (1999) (3)
Genomic aspects of sporadic Parkinson's disease. (2008) (3)
Dopamine and Glutamate in Parkinson’s Disease (2005) (3)
Tranylcypromine Isomers and Parkinson's Disease: New Aspects of an Old Drug 1 (1981) (3)
Effect of room modelling and sensor position on performance assessment of variable air volume control systems (2003) (3)
[Parkinson disease--a mitochondrial myopathy?]. (1993) (3)
Experimental Approach to Alzheimer’s Disease with Emphasis on Insulin Resistance in the Brain (2021) (3)
Target and Additive Drugs in the Treatment of Parkinson’s Disease: A Pilot Study (1985) (2)
Correction to: Coronaviruses: a challenge of today and a call for extended human postmortem brain analyses (2021) (2)
Biochemical aspects of dysphoria: case study for hypothesis generation. (1987) (2)
Molecular Aspects of Neurotransmitter-Receptor Changes in Hepatic Encephalopathy (1984) (2)
[Neurobiologic and pharmacologic studies on the pathogenesis of Parkinson disease]. (1986) (2)
Dopamine and Neurodegeneration (2005) (2)
Hepatolenticular Degeneration: Wilson's Disease (1999) (2)
Clinical Course of Parkinson’s Disease (1983) (2)
SIMTEST-ELEC : A VIRTUAL LABORATORY FOR THE TEST OF TERMINAL CONTROLLERS FOR ELECTRIC HEATING SYSTEMS FOLLOWING A DRAFT EUROPEAN STANDARD (2005) (2)
Altered expression of tau exon 10, clk2 and htra2-ß in post mortem brain of patients with Alzheimer’s disease (2004) (2)
Comprar Handbook of Neurochemistry and Molecular Neurobiology · Degenerative Diseases of the Nervous System | Battistin, Leontino | 9780387303444 | Springer (2007) (2)
Guideline for heat pump field measurements for hydronic heating systems The guideline contains information on what to measure in order to calculate SPF and about the required measurement quality. (2011) (2)
Interactions of neurotoxins with non-NMDA glutamate receptors: an autoradiographic study. (1994) (2)
Reflection of changes in membrane constituents in various regions of Alzheimer brains to differential scanning thermograms. (1990) (2)
Alterations of receptor-G protein-adenylyl cyclase coupling in alcoholics. (1994) (2)
Iron-Induced Dopaminergic Cell Death In Vivo as a Model of Parkinson’s Disease (2021) (2)
Focus on Extrapyramidal Dysfunction (2004) (2)
Dopamine Is a Pathogenetic Factor in HIV-Induced Neuro-AIDS (2002) (2)
Brain Monoamine Oxidase B Activity and Amino Acid Precursor Treatment of Parkinson’s Disease, Depression and Epilepsy (1988) (2)
Quantitative investigations of presenile and senile changes of the human entorhinal region (1990) (2)
[Statistical aspects of the tyrosine-tryptophan diagram in depression (author's transl)]. (1974) (2)
Monoamin-Oxidase-Hemmer (2002) (2)
HUPO Brain Proteome Project: Summary of the pilot phase and introduction of a comprehensive data reprocessing strategy (2006) (2)
The Proteome of Neuromelanin Granules in Dementia with Lewy Bodies (2022) (2)
Journal of Neural Transmission: a scientific journal devoted since 1950 to the translation of neuroscience into clinical practice (2019) (2)
Reply to “CNTF and psychiatric disorders” (1996) (2)
Serum iron status in Rett syndrome (1987) (2)
Monoamine oxidases and their inhibitors (2011) (2)
Sensitivity analysis of a new room model integrating phenomena of air temperature distribution in controller tests (2004) (2)
Is There Any Evidence of Monocytes Involvement in Alzheimer’s Disease? A Pilot Study on Human Postmortem Brain (2021) (2)
In vivo and in vitro effects of glucocorticoids on lectin-induced blastogenesis in atopic dermatitis (2004) (2)
The effects of lisuride and some other dopaminergic agonists on receptor binding in human brain (2005) (2)
Parkinson's disease putamen: Normal concentration of synaptic membrane marker antigens (2005) (2)
[Pathogenesis and neuroprotective therapy trial in chronic degenerative diseases. Status of antioxidants]. (1996) (2)
Walther Birkmayer — The man behind the name (2005) (2)
The Role of Altered Glutathione Status in the Development of Parkinson’s Disease (2018) (2)
Advances in neuroprotection research for neurodegenerative diseases. (2004) (2)
The tyrosine-tryptophan-diagram in a longtime study with depressed patients (2005) (2)
4-hydroxy-3-methoxyphenylglycol as an index of brain noradrenaline turnover in endogenous depression. (1980) (2)
Effect of mutation-induced excess brain concentration of intermediates of the kynurenine pathway of tryptophan metabolism on stress resistance of courtship behavior and communicative sound production in male Drosophila melanogaster (2008) (2)
The Clinical Pathology of Parkinson’s Disease (1983) (2)
[The significance of biogenic amines in cerebral infarction (author's transl)]. (1979) (2)
Some Aspects of Modeling Neuronal Interactions in the Basal Ganglia (1986) (2)
[Schizophrenic psychosis in a patient with Gilles de la Tourette syndrome]. (1988) (2)
Iron in brain function and neurodegenerative disorders. Editorial. (2011) (2)
Monoamine oxidase B; a misunderstood and misjudged enzyme. (1988) (2)
Editorial: Siegfried Hoyer’s concept of Alzheimer pathophysiology (2015) (2)
Therapeutic Drug Monitoring of Antidepressants in Haemodialysis Patients (2012) (2)
[Current preclinical findings on substances against Parkinson's disease]. (2003) (2)
[On the role of MAO B inhibitors and NMDA antagonists in the therapy of Parkinson's disease]. (2010) (2)
An ICT framework for coupling renewables and energy storage in low carbon districts and cities (2013) (2)
Glutamate and Vivian Teichberg: a story about science, medicine, memory and love (2014) (2)
Triplet repeats in clinical subtypes of schizophrenia: variation at the DRPLA (B37 CAG repeat) locus is not associated with periodic catatonia (2005) (2)
Amyotrophic Lateral Sclerosis—Parkinsonism—Dementia of Guam (1999) (2)
Urinary dopamine sulfate conjugates in Parkinson’s disease (1990) (2)
Nicotine Dependence and Its Treatment (2010) (2)
Propranolol Binding in Human Brain: Preliminary Studies (1981) (2)
Effects of α-lipoic acid on mitochondrial dehydrogenases in cortical regions of post-mortem brain in dementia of Alzheimer type (1993) (1)
The reflection of multiple biochemical deficits in nucleus basalis of Meynert of Alzheimer brains to differential scanning thermograms (1989) (1)
Grundlegende Aspekte zur Neurotransmission (1992) (1)
Biochemical events in spontaneous seizures in the mongolian gerbil (1989) (1)
Assessment of MAO inhibitors using postmortem human brain tissue: biochemical and therapeutic implications. (1983) (1)
The role of tyrosine hydroxylase as a key player in neuromelanin synthesis and the association of neuromelanin with Parkinson’s disease (2023) (1)
P1-003: Brain insulin dysfunction triggers plaque-like formations in rat model of sporadic Alzheimer′s disease (2008) (1)
Selegiline for Treating Parkinson’s Disease (2019) (1)
Cloning and functional characterization of the human norepinephrine transporter gene promoter Rapid Communication (1998) (1)
Balancing Operation for the Optimization of Hydronic Networks (2005) (1)
Sleep EEG Variables in Young Schizophrenic and Depressive Patients (1988) (1)
Walther Birkmayer--a tribute on his 80th birthday. (1990) (1)
SEPEMO-Build FINAL REPORT (2012) (1)
P.1.c.044 Efficacy and mechanism of antidyskinetic activity of sarizotan (2006) (1)
Apoptosis inhibition in T cells triggers the expression of proinflammatory cytokines--implications for the CNS. (2006) (1)
Update on Parkinson's Disease Genetics (2007) (1)
The Influence of L5-Hydroxytryptophan (L5-HTP) on Clinical and Biochemical Parameters in Depressive Patients (1984) (1)
[Structure and efferences of the substantia nigra pars compacta in Parkinson's disease]. (2020) (1)
Factors contributing to fluctuations of the dopaminergic nigro-striatal feedback system in Parkinson's disease. (1988) (1)
Gene and Protein Expression Profiling in Parkinson's Disease: Quest for Neuroprotective Drugs (2007) (1)
Univ.- Prof. Dr. med. Siegfried Hoyer 1933–2014 (2014) (1)
beta-Amyloid deposition and prion infection in adult primary brain cell long-term culture model. (2007) (1)
DEPRENYL HAS A BAND OF SELECTIVITY FOR THERAPEUTIC ACTION (1980) (1)
[The combined treatment of Parkinson's disease with L-dopa plus decarboxylase inhibitors (carbidopa, benserazide) (author's transl)]. (1979) (1)
GLUTAMATERGIC MECHANISMS IN THE BRAIN IN MOVEMENT-DISORDERS AND SCHIZOPHRENIA (1994) (1)
CNTF AND PSYCHIATRIC DISORDERS. AUTHORS' REPLY (1996) (1)
[Central neurotransmitters in cerebral ischemia and stroke]. (1983) (1)
Editorial: Walther Birkmayer — A tribute on his 80th birthday (1990) (1)
Branched Chain Amino Acids in Hepatic Failure: Effects on Brain Function (1983) (1)
The Odyssey of Alpha-synuclein and Neuroinflammatory Mediators as Potential Candidates in the Aetiology of Parkinsons Disease (2020) (1)
P2.111 Anti-dyskinetic effects of flibanserin on levodopa-induced dyskinesia in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease (2009) (1)
Histochemistry of MAO-A and MAO-B in the locus coeruleus of the Mongolian gerbil (2005) (1)
Presentation of the AGNP-TDM expert group consensus guideline on „Therapeutic Monitoring of Psychotropic Drugs“ (2004) (1)
Role of iron in 6-hydroxydopamine neurotoxicity. (1999) (1)
Iron and Parkinson’s Disease (1994) (1)
Therapeutic potential of a novel multifunctional iron chelator on cognitive decicits and insulin degrading enzyme expression in a rat model of sporadic Alzheimer's disease (2012) (1)
Therapeutic effects of multifunctional iron-chelating agent in a streptozotocin-induced rat model of sporadic Alzheimer's disease (2013) (1)
Animal Model of Insulin-Resistant Brain State: Intracerebroventricular Streptozotocin Injection Deteriorates Alzheimer-Like Changes in Tg2576 APP-Overexpressing Mice (2011) (1)
A Study on the Multi-Objective Optimisation of District Energy System Performances (2017) (1)
3H-Spiperone Binding to Post Mortem Human Putamen in Paranoid and Nonparanoid Schizophrenics (1985) (1)
Excitatory Amino Acids and Their Antagonists (2015) (1)
Experimental approach to Alzheimer's disease (2013) (1)
Drug- Or Toxin-Induced Movement Disorders (1999) (1)
MAO-B-Hemmer (1992) (1)
Protection by CPP from MPTP-induced neurodegeneration in marmosets (1992) (1)
Molecular heterogeneity of neurotransporters: implications for neurodegeneration. (1997) (1)
L-dopa and (-)-deprenil in the treatment of Parkinson's disease: a long-term study [proceedings]. (1976) (1)
Dopamine D2 -Receptors in Post-mortem Human Brains from Schizophrenic Patients (1990) (1)
Uniform pattern of immunohistochemical localization of serotonin 5-HT2 receptors in human aortic, mitral, pulmonary and tricuspid heart valves: Implication for the pathomechanism of valvular heart disease following treatment with dopamine agonists (2012) (1)
Insulin, Insulin Receptors, and Igf-I Receptors in Post-Mortem Human Brain in Alzheimer’s Disease (1998) (1)
14-67 Dopamine D3 receptor polymorphism and alcohol dependence (1997) (1)
QUANTITATIVE AUTORADIOGRAPHY OF THE NMDA‐RECEPTOR WITH [3H]MK‐801 AND [3H]GLYCINE IN HUMAN HIPPOCAMPUS (1992) (1)
A sensitive procedure for the determination of protein bound 3,4-dihydroxyphenyl-alanine as a marker for posttranslational protein hydroxylation in human frontal cortex, liver, and red blood cells. (2001) (1)
Morbus Parkinson Selegilin (R-(—)-Deprenyl); Movergan® (1988) (1)
Coordination chemical aspects of receptor biochemistry. (1983) (1)
Isoelectric focusing of monoamine oxidase subtypes as identified by MAO inhibitors. (1989) (1)
General properties of 14C-L-Valine-binding to human brain tissue. (1983) (1)
Current Topics in Extrapyramidal Disorders (1980) (1)
Axonal transport of botulinum toxin A from periphery to CNS in sensory and motor nerves (2012) (1)
Transmitter Biochemistry of Human Brain Tissue: Proceedings of the Symposium Held at the 12th CINP Congress, Goteborg, Sweden, June 1980 (1981) (1)
3H-Spiperone binding to peripheral mononuclear cells in psychiatric in-patients (1996) (1)
Modulation of Serotonin Receptors by L-Valine in Hepatic Encephalopathy (1984) (1)
Cholinergic-adrenergic balance: Part 1. Relationship between central and peripheral sensitivities (1990) (1)
In honour of Prof. Dr. W. Birkmayer on the occasion of his 65th birthday (1976) (1)
Brain quinolinic acid in Alzheimer's dementia (1989) (1)
Metabolic and Clinical Effects of Complete Parenteral Nutrition Supplemented by L-Valine in Hepatic Coma (1984) (1)
BRAIN MONOAMINES IN HUMAN CEREBRAL INFACTION (1978) (1)
Consequences of a single short lasting cerebral oligemia and the influence of iron injected into the substantia nigra or in the ventrolateral striatum of the rat. Trigger of Parkinson’s disease pathogenesis? (2004) (1)
Oxidant stress effects on nigral cell death: Prospects for neuroprotection (1994) (1)
LETTER TO THE EDITOR (2009) (0)
Differential effects of neuromelanin and synthetic dopamine melanin on cell lines Inaugural – (2005) (0)
Quantity and Quality Changes of G Protein in Dementia of the Alzheimer Type (1995) (0)
DIFFERENTIAL EFFECTS OF DOPAMINERGIC AGONISTS IN PARKINSONʼS DISEASE (1984) (0)
P2.079 Neuroprotective properties of Poacynum against MPP+-toxicity to dopaminergic cells (2009) (0)
A POST MORTEM HISTOCHEMICAL STUDY OF ALZHEIMER PATIENTS WITH AND WITHOUT DIABETES TYPE II (2011) (0)
Towards a Mathematical Model of Neurological Diseases Affecting the Extrapyramidal Motor System (1985) (0)
SOLVING DIFFERENTIAL EQUATIONS IN TRNSYS WITHOUT PROGRAMMING (2009) (0)
The breakdown of glutamate clearance plays a major role in the pathogenesis of SIV encephalitis (2008) (0)
Erratum (1998) (0)
45 years German Society of Biological Psychiatry (DGBP). (2023) (0)
Topographic Mapping of Biochemical Data (1993) (0)
Histochemical and immunocytochemical examinations of mad-subtypes in the human brain stem (1988) (0)
Towards the development of a coupled model for district simulation: buildings, energy systems and microclimate co-simulation (2018) (0)
Erratum to: Glutamate and Vivian Teichberg: a story about science, medicine, memory and love (2014) (0)
PROGRESSIVE NEURODEGENERA TION OF THE DOPAMINERGIC SYSTEM AND INHIBITION OF THE COMPLEX I INDUCED BY THE CHLORAL-DERIVED (1996) (0)
2.440 Neuroprotection by L-DOPA against chronic MPTP in C57/Bl6 mice (2007) (0)
EFFECTS OF NEUROTRANSMITTERACTIVATION ON COMPUTERIZED EEG‐TOPOGRAPHY (CET) (1992) (0)
A new methodology for the disgn of low energy buildings (2009) (0)
Stress and methylphenidate treatment, both modulate neuronal activity in an animal model for ADHD (2009) (0)
Sites of action of psychoactive drugs and treatment strategies (1989) (0)
85. Dementia in the aged — clinical, psychomental and biochemical correlations (1987) (0)
Clinical neurophysiology and the aging brain (1987) (0)
University of Southern Denmark Melanin and Neuromelanin Fluorescence Studies Focusing on Parkinson's Disease and Its Inherent Risk for Melanoma Leupold, Dieter; Szyc, (2019) (0)
Effect of γ-radiation on the vitamin C and carotenoid contents in several plant products.1. Hips (Rosa canina). (1969) (0)
HIV Dementia: A Neurodegenerative Disorder with Viral Etiology (2007) (0)
EFFECTS OF $sup 60$Co RADIATION ON CARROT SEEDS. I. INVESTIGATIONS ABOUT GERMINATIVE FACULTY AND OBSERVATIONS OF GROWTH. (1971) (0)
DISTRIBUTION OF [3H]‐KAINATE BINDING SITES IN HUMAN BRAIN (1992) (0)
Procedure for determining the neurologically relevant properties of a material (1999) (0)
Schizophrenic Psychoses and Mutations of the Ciliary Neurotrophic Factor (cntf) and Neurotrophin 3 (nt3) Genes: Evidence for the Maldevelopmental Theory (1996) (0)
Lymphocyte adenylate cyclase: a model for putative adrenergic-cholinergic imbalances in affective disorders? (1988) (0)
The new generation of selective monoamine oxidase-inhibitors: biochemical, pharmacological and clinical perspectives. (1988) (0)
Polymorphic monoamine oxidase a and 5-HT-transporter genes: Analysis of interactions with panic disorder (2000) (0)
Mitochondrial Disturbances in Parkinson’s Disease (1994) (0)
Properties of human monoamine oxidase subtypes in one- and two-dimensional electrophoresis (1988) (0)
Impact of Pump Control on Indoor Climate and Energy Efficiency of Hydronic Networks (2006) (0)
2.10.1 THE IRON STORY (2012) (0)
Water Maze STZ 1 2 3 4 5 6 7 8 9 age ( month ) 0 Tr + P 1 2 3 Cryo tissue Paraffin sectionRT (2010) (0)
CEREBRAL AMYLOID ANGIOPATHY DEVELOPMENT IN THE STREPTOZOTOCIN-RAT MODEL OF SPORADIC ALZHEIMER DISEASE (2011) (0)
General introduction and definitions (1989) (0)
DOPAMINE RECEPTORS AND SCHIZOPHRENIA: POST MORTEM HUMAN BRAIN STUDIES (1980) (0)
G-proteins(Go,Gi) in the striatum in Parkinson's disease (1994) (0)
[Changes in organic acids in plasma and cerebrospinal fluid in cerebral infarct]. (1986) (0)
Eco-district design and decision process through building energy and local microclimate assessment (2017) (0)
Letter to the editor (1997) (0)
Endogenous toxic events leading to neurodegeneration:the case of Parkinson's disease (2001) (0)
P-10-11 β-Carbolines (norharmane and harmane) in plasma and 24-h urine during detoxication and controlled abstinence of chronic alcoholics — a longitudinal study (1995) (0)
Is the Point Mutation in Codon 331 of the Mitochondrial ND2 Gene Associated with Alzheimer’s Disease? (1995) (0)
Biostatistical analysis of gene microarrays reveals diverse expression clusters between macaque subspecies in brain SIV infection. (2007) (0)
Neurochemical findings speak against successful monosubstitution therapy among patients with dementia of the Alzheimer type (DAT) (1990) (0)
Lateralisation in Parkinson disease (2018) (0)
O-27-4 cAMP signal cascade in postmortem brains of depressives and suicides (1996) (0)
[Neurotransmitters and ontogenesis of the central nervous system in the human]. (1996) (0)
The effect of methylphenidate treatment on the expression of synaptic vesicle proteins in a mouse model for Attention-Deficit/Hyperactivity Disorder (2007) (0)
Prof. Dr. Moussa B.H. Youdim: an appreciation on the occasion of his 80th birthday (2020) (0)
Walther Birkmayer--a tribute on his 80th birthday. (1990) (0)
Correlation of cognitive deficits and brain cholinesterase activity in streptozotocin-intracerebroventricularly treated rat model of sporadic alzheimer's disease (2011) (0)
Circulating Long Noncoding RNA Signatures Associate With Incident Diabetes in Older Adults: a Prospective Analysis From the VITA Cohort Study. (2023) (0)
Parkinson’s Disease as a Model for Behavioural Studies in Man (1981) (0)
ACETYLCHOLINE AND CHOLINE IN LUMBAR CSF ‐ SPECIFICITY OF MEASUREMENT AND VALUES IN DEMENTIA OF ALZHEIMER TYPE (1992) (0)
BDNF and NT3 concentrations in post-mortem brain tissue of individuals with recurrent depressive disorder (2011) (0)
European quality concepts for heat pumps, Analyses on existing schemes in Europe for training and certification of heat pump installers (2011) (0)
Observations on Human Behaviour (1983) (0)
1.100 Early diagnosis for Parkinson's disease according to whole blood gene profile (2007) (0)
From attention-deficit hyperactivity disorder to sporadic Alzheimer’s disease—Wnt/mTOR pathways hypothesis (2023) (0)
2.408 Time course of amyloid beta pathology in streptozotocin-rat model of sporadic Alzheimer's Disease (2007) (0)
Effect of glucose, fructose, sucrose and maltose on estimation of vitamin C by the Roe and Kuether method. (1971) (0)
NREM Sleep (0)
Altered expression of insulin receptor in hippocampus of streptozotocin intracerebroventricullary treated rats (2007) (0)
Glucocorticoid Receptors on Alzheimer's Disease Mononuclear Leukocytes in (1990) (0)
Practical Applications (2014) (0)
2.432 Therapeutic activity of short synthetic peptides Cortagen and Livagen in Drosophila model for neurodegenerative disorders facilitated by heat shock in mutants of kynurenine pathway (2007) (0)
Influence of $sup 60$Co $gamma$ radiation on $beta$-carotene solutions. II. Qualitative and quantitative investigation of irradiated tributyrin solution (1972) (0)
Therapeutic Drug Monitoring in a Naturalistic Clinical Setting (2005) (0)
Effect of y-radiation on the vitamin C and carotenoid content in several plant products. 3. Paprika (Capsicum annuum). (1970) (0)
Pro-and Antioxidative Properties of Cortical Tissue Preparations from Human Brain Exhibiting NMDA-Receptor Characteristics (1999) (0)
Basic aspects of receptor biochemistry. Proceedings of the international symposium, Vienna, September 10-12, 1982. (1983) (0)
Pharmacotherapy for Cocaine Use Disorders (2021) (0)
EEG differences of CNS activation due to physostigmine and brofaromine in young adults (1989) (0)
Early changes of acetylcholinesterase activity and insulin system in the brain of the streptozotocin- intracerebroventricularly treated rat model of sporadic Alzheimer's disease (2011) (0)
Preface – Special Issue: A Tribute for Prof. Dr. Melvin D. Yahr, M.D. (1917–2004) (2004) (0)
Monoamine oxidase and its selective inhibitors. Satellite symposium of the International Brain Research Organization, Mannheim, March 29-30, 1982. (1983) (0)
Prof. Dr. med. Helmut Beckmann, 22.05.1940–03.09.2006 (2006) (0)
Advances in Research on Neurodegeneration (1999) (0)
[14C]-L-Valine Binding to Post Mortem Frontal Cortex Homogenates in Hepatic Encephalopathy (1984) (0)
Kurt Jellinger An appreciation (2006) (0)
Preface – Special Issue: Neuromelanin (2006) (0)
Prof. Dr. Kurt Jellinger: an appreciation (2017) (0)
Quantitative estimation of vitamin A in feeds by thinlayer chromatography. (1970) (0)
DEPRESSION: IS THE CHOLINERGIC SUPERSENSITIVITY LINKED TO THE CATEGORY OR RATHER TO A DIMENSION LIKE STRESS SENSITIVITY? (1992) (0)
Cholesterol and statins in dementia: To be or not to be relevant? (2009) (0)
P2-022 Streptozotocin-intracerebroventricularly treated rats: Behavioral, neurochemical and structural resembling to the human sporadic type of Alzheimer’s disease (2006) (0)
The presentation of a model-based predictive controller architecture through the interfacing of a dynamic simulation platform DIMOSIM and an optimization modeller OMEGAlpes (2020) (0)
Parkinson's Disease with Psychosis (PDP): Role of 5-HT2A Receptors (2016) (0)
On the occasion of Manfred W. J. Gerlach’s 60th anniversary (2014) (0)
Adrenerg-cholinerge Gleichgewichtshypothese der Depression: der α2-adrenerge Agonist Clonidine antagonisiert nicht das Physostigmin-Syndrom (1993) (0)
Preface – Special Issue: Modelling Alzheimer’s Dementia (2004) (0)
Differential Alterations in Metabolism and Proteolysis-Related Proteins in Human Parkinson’s Disease Substantia Nigra (2017) (0)
IN VIVO AND IN VITRO STUDIES ON THE ACTION OF NEUROTRANSMITTERS IN PARKINSONISM (1992) (0)
Biogenic amines and their metabolites in neurodegenerative diseases (1989) (0)
Author Correction: Common variants in Alzheimer’s disease and risk stratification by polygenic risk scores (2023) (0)
Preface (0)
Gamma irradiation of cyclitols. II. Irradiation of aqueous solution of myo-inosite the presence of oxygen (1975) (0)
Report of the Vth International Symposium on Parkinson's disease — Recent Advances in the Research of Parkinsonism—, Vienna, Austria, September 17–20, 1975 (1976) (0)
Books Received (2001) (0)
Non-Monoaminergig Transmitters, Glia Cell Markers, Cell Adhesion Molecules and Synaptic Proteins in Postmortem Brain Tissue (2002) (0)
H-Spiroperidol Binding to Peripheral Mononuclear Cells in Schizophrenic and Healthy Subjects (2002) (0)
IN VITRO GLUCOCORTICOID‐SENSITIVITY OF LECTIN‐DRIVEN LYMPHOCYTE DNA‐SYNTHESIS AFTER RECOVERY FROM SEVERE MAJOR DEPRESSION. (1992) (0)
Methylphenidate effects on cell growth and maturation in neuronal stem cells (2007) (0)
Subject Index, Vol. 24, 1980 (1980) (0)
Insulin resistant brain state: behavioural, neurochemical and genetical resemblance to sporadic Alzheimer's disease (2006) (0)
Pathobiology and clinics of basal ganglia disorders (1992) (0)
Chapter 8 – Genes and Oxidative Stress in Sporadic and Familial Parkinsonism: cDNA Microarray Studies (2007) (0)
Erratum (1980) (0)
IS METHAMPHETAMINE A THERAPEUTICALLY IMPORTANT METABOLITE OF DEPRENYL (1980) (0)
Neurodegenerative Diseases: Pathophysiology: biochemistry of Parkinson's disease (2005) (0)
Therapeutic potential of a novel multifunctional iron chelator on cognitive decicits and insulin degrading enzyme expression in a rat model of sporadic Alzheimer's disease (2012) (0)
Trace Amine Binding Sites Identical to Receptors (1988) (0)
A tribute to Professor Dr. med. Dipl. Psych. Andreas Warnke (2010) (0)
New Insight into Alzheimer Disease : Demonstration of Fibrin ( ogen )-serum Albumin Insoluble Deposits in Brain Tissue (2006) (0)
FP11-MO-02 Are the total cholesterol and LDL levels valid markers of atherosclerotic risk, or do other more valid markers exist? Controversies in antilipidemic therapy (2009) (0)
Contents, Vol. 24, 1980 (2004) (0)
News items (2004) (0)
DIADEM / Participants Directory (2004) (0)
P.5.b.001 Expression of certain apoptotic regulators in a pharmacological experimental model of Alzheimer's disease (2009) (0)
S-26-1 Free radical scavengers in neuroprotection (1995) (0)
A molecular signature in blood identifies early Parkinson’s disease (2012) (0)
Effect of y-irradiation with 60Co on the vitamin C and carotenoid content in several plant products. 2. Spinach (Spinacia oleracea). (1970) (0)
[14C]-L-valine binding to membranes of the frontal cortex in hepatic encephalopathy (1982) (0)
Discussion: Session 5 — 8 P.M. - 8 February 1993 (1994) (0)
[Changes in and modulation of receptor activity in hepatic encephalopathy]. (1985) (0)
ON TESTING PROCEDURES FOR SHP SYSTEMS Technical Report 5 . 1 (2012) (0)
GTP Binding Proteins in Postmortem Human Brain (1993) (0)
Aminoadamantanes: from treatment of Parkinson’s and Alzheimer’s disease to symptom amelioration of long COVID-19 syndrome? (2023) (0)
Ohio EFNEP Breaking Ground with A New Curriculum (2009) (0)
Interaction between valproic acid and antidepressants/antipsychotics (2014) (0)
706 Reduced amount of adenylyl cyclase type I and type II in dementia of the Alzheimer type (1996) (0)
Energy consumption and green house gases emission reduction of a dwelling (2006) (0)
Lewy bodies, iron, inflammation and neuromelanin: pathological aspects underlying Parkinson’s disease (2023) (0)
The long ascending monoaminergic neuromediator systems in senile dementia of the Alzheimer type (SDAT): Neuropathological and neurochemical findings (1989) (0)
Autonomic-affective dysfunctions (1989) (0)
65-60 Haloperidol concentration in human brain tissue: Effects of dosage, duration of treatment and drug-free time (1997) (0)
Neurotransmitters in old age (1989) (0)
Underlying biochemical and molecular mechanisms of dyskinesia (2005) (0)
1558 – BRAIN MONOAMINES IN HUMAN CEREBRAL INFARCTS (1978) (0)
Environmental and metabolic therapeutic strategies improve anxiety-related behaviour in a rat model of sporadic Alzheimer’s disease (2017) (0)
Professor Georg Becker, MD (1961–2003) (2003) (0)
Oxygen free radicals and cell death (1992) (0)
Editorial – 100 years of Alzheimer’s disease (2006) (0)
Recognition of life-long curiosity in Parkinson Disease treatment developments (2016) (0)
2.433 The possibility of kynurenine metabolites binding to ionotropic glutamate receptors and to calmodulin: data on molecular modeling and Drosophila kynurenic mutants (2007) (0)
TCM Substances in Neuropsychopharmacotherapy: Basic Aspects with a Focus on Depression (2021) (0)
Effects of age, gender, smoking and co-medication on the pharmacokinetics of venlafaxine and O-desmethylvenlafaxine in everyday clinical practice (2009) (0)
Therapeutic galactose effect on metabolic dysfunction and cognition in sporadic rat model of Alzheimer's disease (2018) (0)
[Biochemical aspects of human behavior]. (1973) (0)
Functional effects of neuromelanin and synthetic melanins in model systems (2005) (0)
Gerald Stern (1930–2018) (2020) (0)
Brofaromine (CGP 11 305 A): estimation of plasma concentrations by a biologic technique as compared to liquid chromatography. (1990) (0)
[Metabolic factors in the pathogenesis of consciousness disorders and coma]. (1979) (0)
Modelling and simulation of a low energy building (2005) (0)
Detection and quantitation of tyrosine hydroxylase mRNAs in the human brain (1992) (0)
Interdisciplinary approaches for the understanding of neuropsychiatric disorders (2002) (0)
[Effects of ethanol on GTP-binding protein function in human brain cortex]. (1993) (0)
d/l threo-methylphenidate enantiomers influence on catecholaminergic enzyme activities (2011) (0)
Differential expression of excitatory amino acid transporters in relation to dopaminergic treatment and SIV specific pathology (2006) (0)
Activation of glucagon-like peptide-1 receptors might be a mechanism of the beneficial effects of oral galactose in streptozotocin-induced rat model of sporadic Alzheimer's disease (2018) (0)
Editors' comment (2005) (0)
Modelling of a multizone building for the study of HVAC control systems in a graphical simulation environment (2004) (0)
News from substantia nigra neuromelanin (2005) (0)
Brain-derived neurotrophic factor ( BDNF ) and neurotrophin 3 ( NT 3 ) 4 levels in post-mortem brain tissue from patients with depression 5 compared to healthy individuals – a proof of concept study 6 (2018) (0)
Prof. Dr. Kurt Jellinger: an appreciation on the occasion of his anniversary (2011) (0)
Effects of ethanol of GTP-binding protein in cerebral cortex (1994) (0)
Potential gene expression biomarkers in whole blood of Alzheimer's disease (2009) (0)
Proceedings; Biochemistry of circadian rhythm in endogenous depression. (1975) (0)
[Effect of - 60 Co-irradiation of -carotene solutions. II. Qualitative and quantitative studies of the irradiation of tributyrin solutions]. (1972) (0)
Selegiline's neuroprotective capacity revisited Commentary (2003) (0)
Introductory remarks (1989) (0)
BRAIN MONOAMINES IN HUMAN METABOLIC ENCEPHALOPATHIES (1979) (0)
14-66 Manganese-superoxide dismutase blood levels in alcohol dependent patients during abstinence (1997) (0)
LibriAdvances in Research on Neurodegeneration, Volume 3 & 4, Springer Verlag, Boston/Dordrecht/London (1997) (1998) (0)
[Effect of - 60 Co-irradiation on -carotene solutions. I. Qualitative and quantitative studies of the irradiation of petroleum ether and n-heptane solutions]. (1972) (0)
Advances in research on neurodegeneration, volume 5 (1997) (0)
The significance of neurotransmitters for human behaviour (1989) (0)
ADENOSINE RECEPTOR ANTGONISTS: INTERACTION WITH ADENOSINE A1 RECEPTORS IN HUMAN HIPPOCAMPUS (1992) (0)
HPLC analysis of somatostatin related peptides in putamen of Huntington's Disease patients (2005) (0)
Short Communications Amphetamine and 2-Phenylethylami ne in Post-Mortem Parkinsonian Brain After (--)Deprenyl Administration (1978) (0)
Regional brain studies on indoles and tyrosine in Mongolian gerbils during nutrition with artificial mixtures high in branched chain amino acids compared to a protein rich diet (1979) (0)
Investigation of γ-irradiated palm oil. 1. Qualitative TLC analysis of carotenes and carotenoids and their radiolysis products. 2. Quantitative TLC analysis. (1971) (0)
INVESTIGATION OF THE FAT CHARACTERISTIC FACTOR AND FATTY ACID COMPOSITION OF PALM OIL AFTER GAMMA IRRADIATION. (1971) (0)
[Erratum to: Therapeutic drug monitoring in neuropsychopharmacology : Summary of the consensus guidelines 2017 of the TDM task force of the AGNP]. (2019) (0)
P.4.012 No interaction of apolipoprotein-E and α1-antichymotrypsin polymorphism in alzheimer's disease (1997) (0)
Contents of Volumes in the Metal Ions in Life Sciences Series (2019) (0)
Anxiety and Stress – Translational Perspectives (2019) (0)
Quantification of m R N A of tyrosine hydroxylase and aromatic L-amino acid decarboxylase in the substantia nigra in Parkinson ' s disease and schizophrenia Rapid Communication (0)
Title Page / Contents / Preface / List of Abbreviations (1983) (0)
P-19-8 Adenylyl cyclase immunoreactivity in dementia of the Alzheimer type (1996) (0)
1.011 Early diagnosis for Parkinson's disease according to whole blood gene profile (2007) (0)
Quantifying the Impact of Urban Microclimate in Detailed Urban Building Energy Simulations (2020) (0)
Influence of Age, Gender, Smoking Habits and Comedication on Serum Levels of Venlafaxine and O-Desmethylvenlafaxine under Naturalistic Conditions (2008) (0)
IV.12 Biochemical basis of psychosis in Parkinson's Disease (2006) (0)
Balance and Imbalance of Transsynaptic Neurotransmission as Conditions for Normal and Pathological Behaviour: Examples Only (1990) (0)
Preclinical versus clinical neuroprotection (2009) (0)
Which Phencyclidine-Like N-Methyl-D-Aspartate Receptor Antagonists Are Currently Available for Clinical Use? (1998) (0)
S-44-5 Antidepressant drug-induced modulation of serotonergic gene expression (1996) (0)
Role of neuromelanin as an autoantigen in Parkinson's disease (2013) (0)
DIHYDROPYRIDINE CALCIUM CHANNEL ANTAGONISTS: INTERACTION WITH ADENOSINE UPTAKE SITES IN HUMAN BRAIN. (1992) (0)
Oxidative stress may induce reduction of brain transmitter content in pacific salmon (1996) (0)
49-8 Ciliary neurotrophic factor (CNTF) genotypes and neurotransmitter changes — Relevance for developmental disorders? (1997) (0)
Contents, Vol. 19, Supplement 2, 1986 (1986) (0)
Abstracts Second Congress of the European Society for Clinical Neuropharmacology (1995) (0)
AUTORADIOGRAPHIC DISTRIBUTION OF THE QUISQUALATE RECEPTOR IN HUMAN HIPPOCAMPUS (1992) (0)
The influence of inflammatory reactions on the serum concentration of clozapine (2009) (0)
Neurodegenerative diseases: CSF amines, lactate and clinical findings (1990) (0)
Kurt Jellinger, Doyen of international neuropathology (2021) (0)
Neuroprotection in neurodegeneration (1994) (0)
P.4.026 Increased oxidative stress in alcohol dependent patients as estimated by the in vivo acetylsalicylic acid assay (ASAA) (1996) (0)
Gamma irradiation of cyclic compounds. II. Irradiation of myo-inositol in aqueous solutions under nitrogen (1975) (0)
Improved Reproducibility of Protein Detection in Neuromelanin-containing Human Substantia Nigra Tissue enriched by Laser Microdissection (2020) (0)
Plasma autoantibodies to glial fibrillary acidic protein (GFAP) react with brain areas according to Braak staging of Parkinson’s disease (2022) (0)
Ferritin is located within neuromelanin granules, an iron storing organelle in dopaminergic neurons of the human brain (2007) (0)
Neurochemical investigations in patients with dementia of Alzheimer type and their clinical value (1994) (0)
[Biochemical aspects of human behaviour (author's transl)]. (1973) (0)
1.IS.4. Continuous dopaminergic stimulation (CDS) – new insights (Axxonis Pharma AG/formerly NeuroBiotec) (2007) (0)
Minimizing the inconsistencies of urban building energy simulations through strong microclimate coupling (2019) (0)
Unaltered susceptibility to scrapie in serotonin transporter deficient mice (2006) (0)
ANALYSIS OF PALM OIL AFTER EXPOSURE TO $gamma$-RAYS. 1. QUALITATIVE THIN LAYER CHROMATOGRAPHIC ANALYSIS OF CAROTENES AND CAROTENOIDS AND THEIR PRODUCTS OF RADIOLYSIS. (1971) (0)
Erratum to: Abstracts of the WASAD Congress 2017, in conjunction with the Collaborative Research Centers SFB-TRR 58, Fear, Anxiety, Anxiety Disorders 14–16 September, Würzburg, Germany (2017) (0)
[Metabolic changes in ischemic brain infarct]. (1987) (0)
Amine oxidases and their impact on neurobiology : proceedings of the 4th International Amine Oxidases Workshop, Würzburg, Federal Republic of Germany, July 7-10, 1990 (1990) (0)
Acknowledgment to reviewers (1979) (0)
Glutamate neurotransmission during acute hepatic failure and acute hyperammonemia (1991) (0)
Introducing “High Impact Reviews” (2016) (0)
Figure 45-1, [The direct pathway contains two...]. (1999) (0)
Quantitative investigations in thick frozen sections stained with Gallyas' silver impregnation for the demonstration of Alzheimer changes (1989) (0)
14-3 Calcium/calmodulin-sensitive type I adenylyl cyclase activity is reduced in the Alzheimer's brain (1997) (0)
S21 NEUROMELANIN AND ITS INTERACTION WITH IRON AS A POTENTIAL RISK FACTOR FOR DOPAMINERGIC NEURODEGENERATION UNDERLYING PARKINSON??S DISEASE (2006) (0)
Pathobiochemical Aspects of Parkinson’s Disease and Dementia of Alzheimer Type (1990) (0)
Predictive Validity (2022) (0)
Prof. Dr. Mark A. Smith (2011) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Peter Franz Riederer?

Peter Franz Riederer is affiliated with the following schools:

Peter Franz Riederer's Academic­Influence.com Rankings

Peter Franz Riederer's Degrees

Why Is Peter Franz Riederer Influential?

Peter Franz Riederer's Published Works

Published Works

What Schools Are Affiliated With Peter Franz Riederer?

Peter Franz Riederer's AcademicInfluence.com Rankings